kappika

Building what matters

Kappika Futures Report: The Future of UK Cultivated Meat

(2025–2035)

PERA The Innovation Network

Research Sponsored by Pera International

Contents

1

Executive Summary

Building what matters

1. Executive Summary

Cultivated meat (genuine animal meat grown from cells in controlled bioreactors) is poised to transform the future of protein production. Over the next decade, this technology could significantly reduce the environmental footprint of meat, using a fraction of the land and water of livestock farming and slashing agricultural emissions by up to 92% under renewable energy systems. The conventional global meat industry is a **$1.7 trillion market** and a major climate and biodiversity stressor; even a small shift toward lab-grown meat could yield outsized sustainability gains. Since the first prototype burger in 2013, the cultivated meat sector has expanded to **175+ companies worldwide by 2024**, backed by **$3.1 billion** in investment. Pioneering products have achieved *regulatory firsts* – from Singapore's 2020 approval of cultivated chicken bites to the US and Israel green-lighting cell-based meats in 2023–24. These milestones, alongside the UK's own approval of a cultivated meat ingredient in pet food in 2024, signal momentum toward commercialisation. Yet, **formidable challenges remain**: high production costs, scale-up bottlenecks, regulatory hurdles, and uncertain consumer acceptance mean that cultivated meat's path to supermarkets is not guaranteed.

In the UK, a convergence of world-class bioscience, public research funding, and innovative startups provides a strategic opportunity to lead in this emerging field. The UK government and research agencies have invested in alternative protein innovation hubs and regulatory sandboxes, aiming to position the country at the forefront of cultivated meat science and manufacturing. Several British startups – from **Quest** (developing low-cost cell lines and growth ingredients) to **Ivy Farm** (running Europe's largest cultivated meat pilot plant) – exemplify the UK's burgeoning ecosystem. Over the next 10 years, cultivated meat could develop from today's small pilot batches to a viable industry segment, supplying a modest but growing share of the nation's protein. This foresight report projects that by 2035, cultivated meat might still represent well under 1% of UK meat consumption in base-case scenarios, but with the right breakthroughs and support it could approach **0.5–1% of the market by 2030**, scaling to several percent by the mid-2030s in an optimistic case. Achieving this will require navigating significant risks; technical scale-up, economic viability, consumer trust, and policy alignment; while leveraging the UK's strengths in science, regulation, and industry collaboration. This report provides a comprehensive analysis of the cultivated meat landscape and a strategic outlook for stakeholders, outlining how investors, founders, and policymakers can jointly accelerate progress toward a sustainable, secure, and profitable cultivated meat sector in the UK.

"Over the next decade, this technology could significantly reduce the environmental footprint of meat"

1. Key Messages for LPs, Founders, and Investors

- **For Limited Partners (LPs)**: Cultivated meat represents a *high-impact, long-term investment theme* aligned with climate and sustainability goals. Early deployment of patient capital is needed to bridge the current funding gap as the sector exits its "hype cycle." Global venture funding for cultivated meat fell to only **$139 million in 2024** (down from $1.3 billion in 2021), reflecting tightening capital and longer development timelines. LPs should calibrate expectations for longer horizons and support venture funds and project finance vehicles that can fuel scale-up infrastructure.

  Diversifying across the **value chain (cell lines, bioprocessing tech, ingredients)** can mitigate risk, as enabling technologies may yield returns even if specific end-product startups falter. In short, now is the time to invest counter-cyclically – backing top teams and funds in cultivated meat at today's trough valuations – to capture the upswing as the sector matures toward commercial viability.

- **For Founders (Entrepreneurs)**: Focus on relentless cost reduction and scalability. The technical road to price parity with conventional meat demands innovation in cell line engineering, growth media, and bioreactor design. Founders should prioritise **eliminating expensive inputs** (e.g. replacing foetal bovine serum with food-grade growth media) and adopting **continuous production processes** to improve yields. Collaborating through partnerships or open innovation can help solve common bottlenecks; for example, Quest's partnership with Multus and UCL pooled expertise to develop a low-cost "CULT-GRO" growth platform. Regulatory strategy is as important as technical R&D – early engagement with the UK Food Standards Agency (FSA) can streamline novel foods approval, and pursuing **pet food or hybrid products** initially can be a smart go-to-market to build data and public familiarity.

  Given consumer ambivalence (only **~20–30% of UK consumers currently say they are willing to try cultivated meat** under neutral wording), founders must invest in **consumer education and taste trials** to build trust. Finally, maintain **capital efficiency and clear milestones**. With venture funding tighter, startups that demonstrate tangible progress – e.g. lowering media costs by an order of magnitude or securing a pilot-scale contract – will be best positioned to secure the next funding rounds. This is a marathon, not a sprint: building a cultivated meat company in 2025–2035 will require technical excellence, strategic partnerships, and adept navigation of regulation and public perception.

- **For Investors (VCs, Corporates, and Angels)**: The cultivated meat sector is transitioning from an exploration phase to an execution phase, altering the risk-reward profile. Investors should conduct rigorous due diligence on **technology readiness levels (TRLs)** – distinguishing between hype and actual breakthroughs in cell proliferation rates, bioreactor productivity, and cost of goods. Near-term revenue in this sector will be limited; thus, **strategic corporate investors** (large food and meat companies, ingredient suppliers) have a key role to play alongside venture capital, bringing patience and domain expertise. Many incumbents are already active: e.g. **JBS's $100M investment** in BioTech Foods and construction of a 1,000-tonne cultivated beef plant, or **Tyson and Cargill's stakes** in cultivated meat startups, signal that traditional meat leaders are hedging their bets. Investors should look at **B2B and**

1. Key Messages for LPs, Founders, and Investors

picks-and-shovels opportunities companies providing growth media, cell lines, edible scaffolds, or bioprocess equipment – which can achieve exits through acquisitions by larger suppliers even as consumer product startups take longer to mature. Given that private funding alone is insufficient for the first commercial facilities, investors should also explore **blended finance** models (co-investing with government grants, venture debt, project financing for pilot plants). Overall, the strategic message is to **stay engaged but pragmatic**: support the pioneers driving cost and scale improvements, insist on data-driven milestones, and be prepared for consolidation (many early entrants may merge or exit if they cannot secure funding). Those investors who help the sector solve its scale-up challenges stand to gain early mover advantages in what could be a multi-billion dollar industry by the mid-2030s.

1

Building what matters

> *"investors who help the sector solve its scale-up challenges stand to gain early mover advantages"*

1. Snapshot of Opportunity, Risk, and UK's Positioning

Opportunity vs. Risk Matrix – UK Cultivated Meat (2025–2035):

Dimension	Opportunity (Upside)	Risk/Challenge	UK's Positioning (Strength or Gap)
Market Potential	Access to a huge global meat market (~$1.7 trillion) – even **0.5–1% adoption** yields a multi-billion dollar industry. Early mover advantage in high-value niches (e.g. premium foods, exports).	Uncertain timeline to price parity; high production costs could limit cultivated meat to a premium niche long-term. Competing alt-protein solutions (plant-based, fermentation) may capture market share first.	**UK:** Moderate. Home market is midsized, but UK firms can tap export markets if they scale. The UK lacks the huge domestic demand of the US/ China, but strong trade links could enable export-led growth if products are approved internationally.
Environmental Impact	Major sustainability gains: up to **92% lower GHG emissions** and **90–95% less land use** per unit meat if renewably powered. Supports UK's Net Zero 2050 and biodiversity goals; reduced antibiotic use and waste.	Unproven real-world impact until scaled. If energy for bioreactors is not green, or if media sourcing is not sustainable, actual footprint could disappoint. Need life-cycle transparency to avoid greenwash accusations.	**UK:** Strong. The UK's climate policy leadership and consumer eco-awareness can drive adoption. Abundant renewable energy potential (offshore wind) could power cultivated meat production sustainably. However, need to ensure **grid decarbonisation** continues for full benefits.

1. Snapshot of Opportunity, Risk, and UK's Positioning

Opportunity vs. Risk Matrix – UK Cultivated Meat (2025–2035):

Dimension	Opportunity (Upside)	Risk/Challenge	UK's Positioning (Strength or Gap)
Technology & IP	UK's scientific base offers innovation leadership: world-class tissue engineering, stem cell biology, and bioprocessing research. **4+ dedicated alt-protein research centres** established (e.g. CARMA Hub, NAPIC) foster breakthroughs in cell lines, bioreactors, and food tech. Growing IP portfolio (patents on cell lines, media formulations) can be commercialised or licensed globally.	**Scale-up bottlenecks**: Need to grow cells at 10^8–10^9 L scales – beyond biotech norms – with consistent quality. Current UK pilot capacity (hundreds of litres) is orders of magnitude below what is required for mass production. **Cost of inputs** like growth factors remains high (media can constitute >90% of cost). Risk of tech failure or slower-than-expected progress (e.g. difficulties making structured cuts like steaks).	**UK:** Strength in R&D but **gap in manufacturing**. The UK excels in upstream research (e.g. **UCL's bioprocessing department is world-leading**), and startups like Quest and Multus provide enabling tech. However, the UK has limited domestic biomanufacturing infrastructure for food – no large-scale cultivated meat plants built yet. Bridging from lab to factory is an area where the UK must improve (via investment in scale-up facilities and tech transfer from pharma).
Regulation & Policy	Post-Brexit agility allows the UK to craft pro-cultivation regulations: the FSA's new **'Regulatory Sandbox' program** (launched 2024) aims to fast-track safety assessments for cultivated products. The UK approved Europe's first sale of a cultivated meat ingredient (pet food) in 2024, showing it can be a regulatory pioneer. With supportive policy, the UK could set world-class standards and attract global investment.	Regulatory uncertainty and fragmentation globally: lack of international alignment can complicate trade. The EU's novel food approval is lengthy (and some EU states seek bans), while in the US politics could slow roll-out. The UK must still ensure rigorous safety review, which takes time (FSA novel food approvals ~2+ years). Labelling debates: whether it can be called "meat" or must use terms like "cultivated" will affect consumer perception. Policy risk if political winds shift (e.g. protectionist sentiment for farming).	**UK:** Improving. The UK government recognises alt-proteins for green growth and food security (funding centres, including £16M to NAPIC). The UK has the chance to streamline approval ahead of the EU, giving its companies a head-start. However, the UK currently **lags the US and Singapore** in approving cultivated meat for human consumption. Ensuring a clear, science-based regulatory path (and avoiding moral panic or misinformation in politics) will be critical for UK success.

1. Snapshot of Opportunity, Risk, and UK's Positioning

Opportunity vs. Risk Matrix – UK Cultivated Meat (2025–2035):

Dimension	Opportunity (Upside)	Risk/Challenge	UK's Positioning (Strength or Gap)
Consumer & Societal	Growing public interest in sustainable and ethical food. **59% of UK consumers see benefits** in cultivated meat's animal welfare and environmental promise. Cultivated meat could offer health and food security advantages (free of antibiotics, resilient to supply shocks). If positioned right, it can complement traditional farming and create new skilled jobs in biotech-food manufacturing.	Scepticism and "yuck factor" remain significant. Over 85% of people have concerns about cultivated meat – top worries are food safety, "unnaturalness," and impact on farmers. Risk of public backlash or low uptake if products do not meet taste/price expectations or if communication is mishandled. Social license to operate is not yet secured – some farmers fear an "American style" industrial consolidation that could marginalise them. Also, high price initially could limit consumer trial, creating a perception that this is only for elites or not "real meat."	**UK:** Mixed. The UK public's willingness to try cultivated meat varies widely (16–41% in studies) and has not markedly increased in recent years. The UK has a strong food safety culture and influential animal welfare organisations that could either champion or challenge the new products. A key UK advantage is its robust media and civil society – if stakeholders proactively engage food influencers, chefs, and even farmers in the rollout, they can build trust. Conversely, negative press or activist pushback in the UK could sway EU and other markets. UK producers will need to **earn consumer trust through transparency**, rigorous safety testing, and gradual introduction (e.g. blending cultivated meat into familiar products to normalise it).

1. Snapshot of Opportunity, Risk, and UK's Positioning

Commentary

The **UK's positioning** in cultivated meat is defined by high innovation potential coupled with scale-up gaps. On the upside, the UK boasts strong science, supportive public R&D, and a regulatory willingness to innovate – ingredients for leadership in this nascent industry. The opportunity space is significant: cultivated meat aligns with national priorities (net-zero commitments, post-Brexit tech leadership, food security) and taps into an enormous global market craving sustainable protein. If even a fraction of the UK's £19 billion livestock sector evolves to cell-agriculture over time, it could create thousands of skilled jobs and new value chains.

However, the risks are equally salient. **Economically**, profitability is not assured – cost estimates for cultivated meat today range from **~$16 to $400,000 per kilogram**, highlighting the uncertainty in viable production models. Technologically, bridging laboratory successes to factory-scale output will require engineering feats comparable to the biopharma revolution, but at food-industry cost structures. Societally, failing to bring farmers and consumers along could provoke resistance; cultivated meat could be framed as a threat to cultural food heritage or rural livelihoods if mismanaged.

Thus, the UK's current stance can be summarised as cautiously optimistic: it has many building blocks of an ecosystem (talent, startups, public support) but needs strategic coordination to convert these into competitive advantage. This means investing in scaling infrastructure (pilot plants, contract manufacturing capacity), ensuring agile yet robust regulation, and fostering public dialogue to secure a "social license" for this food innovation.

The next sections of this report delve deeper into these factors – from the global market context to the specific UK opportunity map – to chart a course for converting the promise of cultivated meat into reality over the coming decade.

1

Building what matters

"The UK boasts strong science, supportive public R&D, and a regulatory willingness to innovate."

2

Introduction

Building what matters

2. Introduction

Purpose and Scope: This report provides a forward-looking analysis of the future of meat production in the UK, focusing exclusively on lab-grown or "cultivated" meat and its development over the next 10 years. Commissioned as a Kappika Futures foresight study, it is intended to inform Limited Partners (LPs), startup founders, investors, and policymakers about the opportunities, risks, and strategic actions in this rapidly evolving domain. While alternative proteins include plant-based and fermentation-derived foods, we concentrate here on **cell-cultivated meat** – genuine animal muscle and fat tissues grown from cells – as a distinct pillar expected to complement or disrupt conventional livestock farming. The report addresses why this topic is urgent now: climate imperatives, technological tipping points, and shifting consumer preferences are converging to make the 2025–2035 period critical for determining whether cultivated meat can scale from prototypes to a viable industry.

Urgency of Timing: The coming decade represents a make-or-break window for cultivated meat. On one hand, global pressures are mounting to find sustainable protein sources. The UK's legally binding **Net Zero 2050** target and global climate goals cannot be met without addressing food-system emissions (livestock alone accounts for ~14–18% of global GHG emissions and widespread deforestation). Concerns over pandemics and antibiotic resistance add further impetus to reduce reliance on industrial animal farming. Cultivated meat offers a novel solution: it decouples meat production from livestock, theoretically allowing more output with far less environmental impact and no slaughter. This promise has driven an influx of R&D since the 2010s. But as of 2025, **the viability of the cultivated meat sector is still unclear**.

Technical barriers and high costs have kept cultivated meat at the demonstration stage, with only small tasting events and limited releases (mostly abroad). Without accelerated progress in the next decade, cultivated meat risks stalling in the "valley of death" between lab and market. Conversely, timely innovations and supportive policy in the next 10 years could position cultivated meat to enter mainstream diets by the 2030s. For the UK, which is charting its own regulatory path post-Brexit, the next few years are pivotal to set up frameworks that could either nurture a new industry or leave it playing catch-up to the US, Asia, and others. This futures report is thus timely – it examines the current state of cultivated meat and projects future scenarios, emphasising what actions now could yield desired outcomes by 2035.

Methodology: Our analysis employs a mixed-methods approach typical of **Kappika Futures** studies, combining evidence-based trend analysis with scenario planning. We conducted an extensive literature review of scientific papers, industry reports, investment data, and policy papers (including UK Parliamentary POSTnotes and Good Food Institute reports) to ground our assumptions in current realities. Connected sources ranged from academic findings on bioprocess costs and life cycle impacts to market research on consumer attitudes and expert interviews (implicitly drawn from quotes and statements in media). Using this research, we identified key **drivers, uncertainties, and indicators** for cultivated meat. We then developed multiple **scenarios** for 2030–2035, quantifying potential outcomes (market size, adoption rates, etc.) under different conditions.

kappika
Building what matters

"The coming decade represents a make-or-break window for cultivated meat"

2. Introduction

The report also includes a “Snapshot” opportunity-risk matrix, and a “UK Opportunity Map” to visualise strengths like regional R&D clusters. All information is cited from reputable sources (references are included in the Appendices). In line with future best practices, we adopt a **10-year time horizon**: long enough for transformative change (e.g. new production facilities, regulatory regimes) yet close enough to require concrete planning by today’s decision-makers. We conclude with actionable recommendations tailored to investors, founders, and policymakers, recognising that a coordinated effort is needed to overcome barriers. By outlining signals to watch and strategic choices to make, this report aims to equip stakeholders with the insight to shape a positive future for cultivated meat in the UK.

Report Structure: Following this introduction, the report is organised into thematic sections: **Market Landscape and Global Context** examines worldwide trends and benchmarks that frame the cultivated meat sector. **UK Opportunity Map** assesses Britain’s scientific and industrial ecosystem for cellular agriculture. We then profile the current **Startups and Commercial Activity** – including a case study on Quest – and the evolving **Investment and Incumbent Landscape** of major players. Next, we analyse **Risks and Barriers** spanning technology, regulation, market and talent issues. Building on those insights, we present **Signals and Scenarios** for how the 2035 horizon might unfold, with early indicators to monitor. Finally, the report offers **Implications and Recommendations** for LPs, founders, and policymakers to drive a favourable outcome, followed by Appendices (glossary, references, methodology, acknowledgements) for further context. Throughout, the tone is analytical and forward-looking, focusing on near-term (next decade) developments with an emphasis on the UK’s strategic interests. By mapping both the opportunities and the pitfalls, we hope this report serves as a practical guide for readers to navigate the cultivated meat revolution on the cusp of moving from science fiction to supermarket reality.

“The cultivated meat revolution on is the cusp of moving from science fiction to supermarket reality.”

3

Market Landscape and Global Context

Building what matters

3. Market Landscape and Global Context

Macro Drivers of Cultivated Meat: The rise of cultivated meat is best understood in the context of global mega-trends in food and sustainability. At its core, cultivated meat addresses a fundamental challenge: how to meet growing protein demand without overstretching planetary limits. The world population is projected to reach ~9.7 billion by 2050, with demand for meat and seafood rising accordingly. Conventional animal agriculture is resource-intensive and polluting, for example, producing 1 kg of beef can require **15,000+ litres of water, 30+ m² of land, and emit ~36 kg CO_2**. The current food system, worth $8 trillion, imposes an estimated **$12 trillion in negative externalities** (environmental and health costs) each year. These stark numbers have galvanised interest in alternative protein solutions. Cultivated meat offers a paradigm shift: rather than raising an entire animal (with all the feed, land, waste and methane that entails), we could grow only the edible parts – muscle and fat – directly from cells. Early life-cycle analyses suggest dramatic efficiency gains. One study found that if renewable energy is used, cultivated meat could cut **greenhouse gas emissions by 92%** and land use by 90% compared to conventionally farmed beef. Another analysis cited by the Good Food Institute projected that cultivated poultry needs **60–300% less land**, and beef **2000–4000% less land**, than their farmed equivalents if scaled efficiently. These potential gains in land sparing, along with avoiding antibiotics and reducing zoonotic disease risk, make a strong environmental and public health case for cultivated meat.

Beyond sustainability, **food security and resilience** are key drivers. The COVID-19 pandemic and geopolitical conflicts have exposed vulnerabilities in global supply chains, including meat processing plants and feed imports. Cultivated meat production – which could eventually be done in modular, urban facilities – might shorten supply chains and insulate protein production from diseases (no livestock herds that can be culled) and climate shocks. For countries like the UK that import a large share of their protein, developing domestic cultured meat capacity is attractive for self-sufficiency. **Animal welfare** is another significant driver: growing meat from cells could eliminate the need to slaughter billions of animals annually, a fact that appeals to ethical consumers and organisations. Altogether, these drivers form a powerful narrative: cultivated meat could help feed more people with fewer resources, mitigating deforestation, biodiversity loss, and antibiotic overuse while still delivering the experience of eating real meat. This narrative has captured the imagination of futurists, investors, and increasingly governments – but turning it into reality is the task at hand.

Sectoral Trends and Global Benchmarks: Since the field's inception in the 2010s, the cultivated meat sector has evolved from academic proof-of-concepts to an entrepreneurial ecosystem. As of 2024, there are **over 175 startups and companies across six continents** devoted to cultivated meat (including seafood) or its enabling technologies. Cumulative private investment crossed **$3 billion** by late 2024, with large infusions during 2020–2021's wave of enthusiasm. However, investment trends have recently cooled: funding in 2022 was $917 million and in 2023 about $230 million, before dropping sharply in 2024 (only ~$139 million, or $84 million excluding one outlier deal). This reflects broader market conditions (higher interest rates, cautious VC climate) and a realisation that cultivated meat is a longer-term play than initially hyped. **Valuations and investor sentiment** have tempered, shifting from "growth at all costs" to a focus on core technology milestones and path-to-market clarity.

bappla
Building what matters

"The world population is projected to reach ~9.7 billion by 2050"

3. Market Landscape and Global Context

Despite the pullback, **2024 marked significant milestones** in technology and regulation. For instance, several companies achieved critical path-to-market breakthroughs: **UPSIDE Foods and GOOD Meat** in the U.S. received regulatory clearance to sell their cultivated chicken (mid-2023), leading to the first restaurant servings in California. By early 2024, **Israel approved cultivated meat** for consumption, joining the U.S. and Singapore as pioneers. Meanwhile, Italy and some U.S. states saw backlash in the form of proposed bans or labelling restrictions – highlighting that politics can cut both ways. On the tech front, **production scale is inching upward**. The Australian startup **Vow** is now operating a 20,000 L bioreactor (the largest reported to date) for cultivated quail meat and is on track to achieve unit economics that could make it profitable on a marginal basis. In Europe, meat giant **JBS broke ground in 2023 on a plant in Spain** stated to produce 1,000 metric tons of cultivated beef annually (scalable to 4,000 tons) – a facility poised to be the world's largest, dwarfing pilot plants elsewhere. These are still small numbers relative to global meat output (1000 tons is a speck in the >300 million ton world meat market), but they are important benchmarks signalling that industrialisation is starting.

Cost Trajectory: One of the most closely watched trends is the cost per kilogram of cultivated meat. This has fallen dramatically from the $330,000 publicity price of Mark Post's 2013 burger to about **$100–$300 per pound** for prototypes by 2020 (in internal calculations). Yet it remains far above conventional meat prices (which are $2–$10 per pound). Key cost drivers are the growth medium (the "cell feed") and capital expenditures for bioprocessing. Notably, **growth media cost reductions** have been a bright spot: as of 2024, researchers from Believer Meats and Hebrew University reported achieving media costs of **$0.63 per Liter**, a >99% reduction from pharma-grade benchmarks, via use of food-grade ingredients and continuous recycling. This kind of progress was faster than many anticipated and suggests that substantial cost improvement is feasible with innovation. Furthermore, companies are introducing new bioreactor designs optimised for cell ag (e.g. **fixed-bed and perfusion bioreactors** for adherent cell growth) and demonstrating continuous production methods that drive efficiency up. A 2023 techno-economic analysis by SuperMeat, for example, outlined how continuous processing at large scale could bring the cost of cultivated chicken to near parity with high-end conventional chicken – though such findings are as yet theoretical.

Still, experts acknowledge that no single "silver bullet" will instantly solve the cost challenge. Instead, cumulative incremental gains are needed across the board: cheaper growth factors (via synthetic biology or plant-derived alternatives), better-performing cell lines (with doubling times and growth densities improved through cell line development or genetic tweaks), and high-density bioprocessing to maximise output per tank. **The Good Food Institute's 2024 report** emphasises that first-of-a-kind large facilities will likely need **public co-funding or non-VC capital**, because the economics are unproven and traditional VC is not well-suited to finance factories. Encouragingly, governments around the world have started to step in. For instance, **China and India** made major public funding commitments to cultivated meat science in recent years; **Japan, Singapore, and South Korea** have government-supported R&D programs and regulatory roadmaps; the **EU** launched a €7 million "FEASTS" consortium to study cultivated meat's role and the **UK** (as detailed later) has invested in multiple research hubs. This public sector interest is a trend to watch – it could de-risk technologies and signal to markets that cultivated meat is moving from fringe to strategic priority..

"The U.S. received regulatory clearance to sell their cultivated chicken, leading to the first restaurant servings in California"

3. Market Landscape and Global Context

Global Market Size and Forecasts: Given the uncertainties, forecasts for cultivated meat's market growth vary wildly. On the conservative end, **McKinsey (2021)** projected that by 2030, cultivated meat might supply about **0.5% of the world's meat** (by volume) – a small fraction, but meaningful in absolute terms (perhaps a few hundred thousand tonnes globally). Other analyses focus on value: a report for Ivy Farm by Oxford Economics foresees a **$15 billion global cultivated meat market by 2030**, while some market research firms project anywhere from ~$6 billion to ~$25 billion by 2030 depending on uptake rate. Looking further out, **BCG (2021)** estimated cultivated meat could have ~6% of the alternative protein market by 2035 – which, if alternative proteins as a whole reach e.g. 11% of the total meat market, implies cultivated meat might be ~0.5–1% of global meat in 2035. More optimistic advocates, like RethinkX, have sketched disruptive scenarios where by 2040 cultivated meat reaches cost parity and takes double-digit percentages of market share, but these are speculative. A commonly cited figure is from Allied Research: a **$229 billion market by 2050**, which would be about 10% of the projected global meat market by then – an assumption of eventual large-scale adoption.

For the **next 10 years**, a reasonable consensus is that cultivated meat will remain a **minor but fast-growing segment**. It may see its first hundreds of millions of dollars in revenue globally by the late 2020s, primarily through high-end restaurants, specialty retailers, and product launches in receptive urban markets. By 2035, with regulatory approvals broadening, production costs halved or better, and some real-world success stories, cultivated meat could move from novelty to an accepted (if still premium) part of the protein aisle. The shape of adoption might vary by region: Asia (especially Singapore, Japan, China) and North America are expected to lead, given heavy investment and consumer tech-forward mindset in some demographics, while Europe's uptake may depend on regulatory speed and cultural factors. It is notable that Asia-Pacific and North America already account for an estimated **95% of the current cultivated meat market value** (albeit tiny), reflecting where the first sales have occurred. Europe (including the UK) is playing catch-up – which is why the UK's actions in the next few years are crucial if it wants to be a producer, not just an importer, of cultured meat products.

Consumer Attitudes and Market Entry Strategies: A crucial aspect of market landscape is how consumers perceive lab-grown meat. Global surveys reveal a spectrum of opinions, with younger generations, urban dwellers, and those with higher education levels more open to trying it. In the UK specifically, as mentioned, only a minority (~1/5 to 1/3) say they are willing to eat cultivated meat at this stage, and many remain unsure. However, a majority acknowledge potential benefits (especially for animal welfare and the environment), which suggests curiosity and conditional acceptance – people want to know it is safe, natural enough, and will not harm farmers. The top concerns – food safety and "unnaturalness" – indicate that transparent communication and branding will be pivotal. Many companies have moved away from the term "lab-grown" to terms like "cultivated" or "cell-based" meat, precisely because framing affects acceptance (studies show **using the term "cultivated" and emphasising benefits raises willingness to try** vs. saying "lab-grown" with no context).

bappla
Building what matters

"The UK's actions in the next few years are crucial if it wants to be a producer."

Market entry is likely to be gradual and strategic. Initial products are often **hybrid foods** – for instance, a chicken nugget that is, say, 60% plant-based protein combined with 40% cultivated chicken cells, or a beef burger that mixes cultivated fat with plant protein to enhance flavour. This approach stretches the still-expensive cultivated biomass further and also eases consumers in (the product is not entirely unfamiliar in texture). Indeed, the **first retail cultivated meat product** ever, launched in Singapore in 2023, was a hybrid chicken nugget containing cultivated meat as a minority ingredient. In 2025, the UK's first foray is a pet treat containing 4% cultivated chicken by Meatly – effectively a low-risk trial before human food use. Over the next decade, we can expect to see **more pilot products in restaurants and limited releases** (with premium positioning and storytelling around sustainability). As production volumes rise and costs fall, companies will target gourmet and specialty retail channels, perhaps collaborating with celebrity chefs or upscale grocery chains to build cachet. By the early 2030s, if things go well, cultivated meat may be offered as an option in mainstream retail for certain products (ground meat, meatballs, dim sum, etc.), albeit at a price premium akin to organic or free-range meat.

Benchmarking the UK: Internationally, a few countries have set themselves up as cultivated meat leaders. **Singapore** stands out for being first to approve and actively courting companies to set up pilot production there (it aims to produce 30% of its food locally by 2030 under its "30 by 30" goal and sees alt-proteins as key). **Israel** has a vibrant startup scene (over 10 cultivated meat startups, significant government grants, and now domestic regulatory approval). The **United States** has the largest number of companies and has just overcome its first regulatory hurdles; big players like UPSIDE Foods and Believer Meats are building pilot plants on US soil (Believer's North Carolina facility aims for several thousand tons capacity eventually). **China** has signalled interest in not falling behind – while no products are approved there yet, major research programs in cellular agriculture have been funded and a state-backed innovation centre launched in 2022. On the corporate side, traditional meat companies globally are hedging, apart from JBS, **Tyson Foods** in the US invested in UPSIDE and Future Meat (Israel), **Cargill** invested in Aleph Farms (Israel) and Meatable (Netherlands), and **BRF (Brazil)** invested in Aleph too. This indicates incumbents are likely to help drive commercialisation once the tech is closer to viability, providing distribution muscle and manufacturing know-how (and also possibly lobbying support for favourable regulation).

For the UK to gauge its competitive stance, these benchmarks matter. The UK currently has zero cultivated meat products approved for human consumption (as of mid-2025) – similar to the EU, behind the US/Asia front-runners. However, it has a chance to move faster than the EU, given its independent regulator, and possibly approve a product by 2025–26 (the FSA sandbox aims to clear **two products for safety by 2025–26**). On the industry side, the UK's startup scene, while vibrant, is smaller in absolute numbers than the US or Israel. One metric: of the ~$3 billion invested globally, only a modest fraction has gone to UK-based startups – many of the top-funded firms (Memphis/UPSIDE, Eat Just/GOOD Meat, Mosa Meat, etc.) are outside the UK. The UK's largest cultivated meat fundraising to date is Ivy Farm's ~$35 million (including grants) and HigherSteaks/Uncommon's ~$30 million; no UK cultivated meat startup yet has a war chest comparable to the $100M+ rounds seen elsewhere. Agronomics, a UK-based investment fund, is notable for investing globally (with stakes in Mosa, Meatable,

"Singapore aims to produce 30% of its food locally by 2030 under its "30 by 30" goal."

VitroLabs, etc.), but some of those companies it backs are overseas. This suggests that the UK punches above its weight in research but needs to attract more capital and scale-up activity domestically to keep up. The next section will explore the UK's specific strengths and gaps in detail, mapping the scientific base, IP generation, regional clusters, and translational infrastructure that could enable the country to carve out a leadership role in cultivated meat despite its medium size..

4

UK Opportunity Map

Building what matters

4. UK Opportunity Map (Science, IP, Clusters, Translational Hubs)

The United Kingdom possesses several **strategic advantages** that could enable it to become a hub for cultivated meat innovation. This opportunity map examines the key pillars: scientific research and talent, intellectual property (IP) and spin-outs, geographic clusters of activity, and the translational infrastructure (from labs to pilot plants) turning science into commercial products.

World-Class Science & Engineering Base: The UK's academic institutions are at the forefront of many disciplines underpinning cultivated meat. Notably, **cellular agriculture is inherently interdisciplinary**, drawing on cell biology, tissue engineering, chemical engineering, food science, and even materials science. The UK is home to globally recognised research groups in these fields. For example, **University College London (UCL)** hosts the Advanced Centre for Biochemical Engineering, which is the largest academic bioprocessing group in the world. UCL and other universities have deep expertise in fermenters, bioreactors, and process scale-up thanks to decades of biopharma and industrial biotech research. This knowledge is directly transferable to cultivated meat bioprocess design (the difference being producing a food commodity at low cost versus a drug at high cost). In tissue engineering, UK universities like **Cambridge, Oxford, Bath, and Nottingham** have done seminal work on scaffolds, 3D tissues, and regenerative medicine – much of which overlaps with growing muscle tissue for food. For instance, Professor Marianne Ellis's group at University of Bath (now leading the CARMA hub) has worked on hollow-fibre bioreactors for cell culture, originally for medical applications, now pivoting to meat cells.

In the past two years, the UK's commitment to alternative protein R&D has *materialised in major funding for dedicated centres*. **Four new research hubs** stand out:

- **CARMA (Cellular Agriculture Manufacturing Hub)**: Launched in 2023 with £12 million from EPSRC, CARMA is led by University of Bath with a consortium including Aberystwyth, Bristol, Birmingham, Royal Agricultural University, and UCL. Its mission is to solve the manufacturing challenges for cultivated meat at scale, over a 7-year program. CARMA is tackling everything from novel bioreactor design and media formulation to socio-economic integration (they run public and stakeholder forums with farmers to discuss how cellular agriculture can fit into society). It's the UK's flagship academic project on making cultivated meat production feasible and economically viable – an important asset as no equivalent large-scale manufacturing program exists elsewhere in Europe.

- **NAPIC (National Alternative Protein Innovation Centre)**: Opened in late 2024 with **£15 million from BBSRC and Innovate UK**, hosted by University of Leeds and co-led by James Hutton Institute, Sheffield, and Imperial College. NAPIC takes a broader alt-protein scope (plant-based, fermentation, and cultivated) but is highly relevant. Its mandate is to make alternative proteins mainstream, focusing on consumer integration and open-access innovation. Crucially, NAPIC's *PROCESS* pillar is aimed at scaling up cultivated meat using AI-guided models, and *PEOPLE* pillar at affordability and training. With 30+ researchers and 150 partners engaged, NAPIC places the UK among the few countries (with e.g. Singapore's Future Ready Food Safety Hub) that have a national centre addressing alt-protein end-to-end – from technical R&D to consumer acceptance.

4

"In the past two years, the UK's commitment to alternative protein R&D has materialised in major funding for dedicated centres."

4. UK Opportunity Map (Science, IP, Clusters, Translational Hubs)

- **Imperial College London's Hubs (Microbial Food Hub & Bezos Centre)**: Imperial now hosts two synergistic centres at its White City campus. The **Microbial Food Hub**, backed by **£12.6 million UKRI funding**, focuses on precision fermentation and is more about fermentation-derived proteins (like dairy proteins from microbes). However, its co-lead, Dr. Rodrigo Ledesma-Amaro, runs both that and the new **Bezos Centre for Sustainable Protein** – with a major infusion of **$30 million (£24 m) from the Bezos Earth Fund**. The Bezos Centre has an explicitly broad remit across cultivated, plant-based, and fermentation, aiming to overcome scaling obstacles via engineering biology approaches. It is global in scope, partnering Imperial with Tufts, Denmark's DTU, NUS Singapore, NC State, etc. This puts the UK in a leadership role coordinating international research. The Bezos Centre's pillars include research (40 teams), translation (spinouts and partnerships), and education (new Masters/PhDs in alt-protein) – building the talent pipeline. They will use Imperial's new biofoundry capabilities to develop robust cell lines and affordable media and even explore integrating plant and cultivated products for better foods. The presence of this centre signals to the world that London is a hotbed for sustainable protein science, comparable to initiatives in the US or Asia.

- **Others**: Additionally, the UK has initiatives like the **Good Food Institute Europe's grant programs, the Engineering Biology Transition Awards**, and private accelerators. While not "centres" per se, organisations such as **Cellular Agriculture UK** (a non-profit network co-founded by farmers and cell-ag advocates) help convene academia, industry, and the public. And beyond formal alt-protein centres, the UK's strength in **stem cell research (e.g. Francis Crick Institute, Stem Cell Institute Cambridge)** provides a foundational knowledge for cultured meat cell line development. **Intellectual Property and Innovations**: The UK's robust research has already yielded valuable IP in the cultivated meat space. For instance, **Roslin Technologies**, an Edinburgh-based venture linked to the Roslin Institute, has developed commercial animal cell lines (pig and chicken) for use by cultivated meat companies – they claim one of the world's first pluripotent pig cell lines that can self-renew indefinitely, a crucial IP asset for scaling pork. Roslin's cell lines are being licensed globally and used for both human food and pet food products. Meanwhile, **Quest** – profiled in the next section – has patent-pending formulations for microcarriers and serum-free media. The fact that Quest is developing an **edible microcarrier** (a scaffold on which cells can grow that does not need removal) and a **low-cost FBS replacement** is significant: if patented and proven, these could become enabling technologies widely adopted across the industry. The UK also has patents coming out of university spin-offs: e.g. **CellulaREvolution*** (a Newcastle University spinout) has a patented continuous cell culture technology using peptide coatings that allow cells to grow adherently but be harvested continuously – initially targeting cell therapy, now applied to cell-ag for higher productivity. **Higher Steaks (now Uncommon*)**, a Cambridge-based startup, has developed processes for deriving muscle and fat from induced pluripotent stem cells; while much of their IP is trade secret, they have filed patents on differentiation protocols and bioreactor designs for cultivated pork.

Furthermore, British researchers are contributing to open-access science: for example, the **CARMA hub** has a work package to develop open-source cell lines and media. The idea is to avoid a situation where a few corporations lock up all the core IP – instead, make some tools widely available to spur the whole field (much like open-source software).

** no longer trading*

4

bappla
Building what matters

"The presence of The Bezos Centre signals to the world that London is a hotbed for sustainable protein science."

4. UK Opportunity Map (Science, IP, Clusters, Translational Hubs)

The UK's tradition of **strong but balanced IP regimes** (through universities, tech transfer offices, and collaborative R&D) is an asset – it can encourage innovation while ensuring publicly funded breakthroughs benefit the broader community and UK industry. In summary, the UK's IP portfolio in cultivated meat spans cell biology (cell lines, genetic tweaks), process engineering (bioreactors, continuous culture), and product formulation (scaffolds, media, end-product textures). This knowledge can generate licensing revenue and attract partnerships; for example, overseas companies might partner with a UK firm to use its cell line for a new product, paying royalties back to the UK.

Geographical Clusters and Talent Pools: The cultivated meat sector in the UK, while small, is concentrated in a few emerging clusters:

- **London–Cambridge–Oxford "Golden Triangle"**: As in biotech, this region hosts a disproportionate share of startups and research. London offers Imperial College (with its White City innovation campus, housing startups like Multus) and UCL (with links to Quest, and its new Engineering Biology centre). London is also where Hoxton Farms (cultivated fat startup) and Multus (culture media startup) are based. Cambridge has been home to Uncommon* (HigherSteaks) and various biotech investors. Oxford has **Ivy Farm** (spun from Oxford University research), which built its pilot plant at the ARC Oxford site and also hosts an ecosystem of engineering talent. These areas benefit from access to top universities and an existing life-sciences industry workforce (many cultivated meat scientists in startups hail from biomedical or pharma backgrounds in these cities). Notably, Ivy Farm's plant in Oxford is an anchor, being Europe's largest pilot facility at 600 L scale – this attracts attention and could draw suppliers, partners, and skilled workers to the area.

- **Midlands and North (Manufacturing Belt)**: The UK's Midlands, including Nottingham, Birmingham, and Leeds, have a strong biotech and food science presence. Quest is headquartered in Birmingham (and works with U. Birmingham and UCL). Nottingham is where some of the Quest team studied and possibly has activity via BioCity incubators. Leeds hosts NAPIC, which involves the University of Sheffield and others in the North. As the cultivated meat industry matures, these regions with industrial manufacturing heritage could be ideal for scaling production – they have space, cheaper costs than London, and relevant skill bases (e.g. biochemists, chemical engineers from their universities). The **National Biomanufacturing Centre** in Darlington (focused on biologics) might even provide a template for how government can seed a facility that companies use collaboratively. The North-East (Newcastle) gave rise to CellulaREvolution*; Scotland (through Roslin Tech in Edinburgh) is another node of innovation. If we map it, the UK's cluster network might look like: London/Cambridge (R&D, HQs, finance) linking to Oxford/Birmingham/Leeds (pilot production, translational research) and out to Newcastle/Scotland (specialty tech and primary cell resources).

- **Translational Hubs and Catapults**: The UK has institutions designed to bridge lab to industry – for example, the **Cell and Gene Therapy Catapult** (CGT Catapult) in Stevenage, where Quest's COO came from. While focused on medical therapies, CGT Catapult has large bioreactors and expertise in scaling cell production under GMP, which could potentially crossover or at least provide talent to cell-ag startups. Some cultivated meat startups have indeed hired ex-pharma bioprocess engineers and leveraged contract development organisations that historically served pharma.

** no longer trading*

4

bappla
Building what matters

"Those regions with industrial manufacturing heritage could be ideal for scaling production."

The presence of such infrastructure (pilot plants, catapults, high-tech business parks) means the UK does not start from zero in building a manufacturing supply chain – it can repurpose or adapt facilities to food-grade standards.

- **Synergy with Food & Agri Sectors**: Cultivated meat does not exist in a vacuum – integration with the broader food industry can form clusters. For example, the UK has major food science hubs like **Reading University**, where there's an agrifood research focus (including studies on how farmers view cultured meat). Traditional meat processing companies in the UK (like Cranswick, ABP) might eventually partner with cell-ag firms or convert part of their facilities to cultivated meat processing (for instance, using their expertise in forming sausages or burgers, regardless of how the meat is sourced). If that happens, regions with existing meat-processing could become hybrid clusters (e.g. East Yorkshire or Northern Ireland). At the moment, however, most UK incumbents are in wait-and-see mode, so the cluster map is primarily defined by startups and academia.

Strengths and Gaps: Summarising the opportunity map, the **UK's strengths** lie in its rich **talent pool and collaborative research environment**. The country is producing PhDs and engineers who are well-versed in the underlying science – a critical factor as talent scarcity is a known bottleneck globally (few people have experience in large-scale tissue culture). The new centres (CARMA, NAPIC, etc.) not only tackle technical problems but also train students specifically in alt-proteins, which will enlarge the skilled workforce. Moreover, UK universities are increasingly open to entrepreneurship; many of the startups (Ivy Farm, Quest, Uncommon*) are university spin-outs or have professors as co-founders, meaning knowledge is flowing from academia to industry efficiently.

A notable **gap** is late-stage funding and manufacturing muscle. While the UK has many early-stage startups, none has yet built a demonstration plant at true commercial scale on par with the facilities in the US (Believer's 200,000 sq. ft plant underway) or JBS's planned site in Spain. Ivy Farm's pilot (18,000 sq. ft, 600 L bioreactor) is a start, but to produce thousands of tons, they or others will need to raise much larger capital rounds or partnerships. The UK's venture capital scene for food tech, though growing (e.g. dedicated funds like Synthesis Capital in London), is smaller than the US/Asia, and British startups often seek US or European investors for big rounds. Bridging this gap may require government support (e.g. matching funds, loan guarantees for building production sites) to ensure that when a company is ready to scale, it doesn't relocate production abroad. Another gap is integration with agriculture – while the UK has funded studies on implications for farmers, it will need actual programs to help rural areas participate (converting some dairy facilities to grow media production sites using local crops, etc., as a fanciful example).

In conclusion, the UK's opportunity map for cultivated meat is promising but not yet complete. The pieces – top-notch science, early startups, supportive policy rhetoric, and initial funding – are mostly in place. The coming years should focus on filling the critical missing pieces: facilitating scale-up capital and physical infrastructure, protecting, and leveraging IP (so UK inventions yield UK jobs), and linking the new cellular agriculture sector with the country's existing strengths in agriculture and food manufacturing. The next section will examine who is already active on the ground – the startups, scaleups, and commercial actors driving the UK's cultivated meat scene – to give a concrete sense of how this opportunity is being pursued in practice.

** no longer trading*

4

Building what matters

"The UK's strengths lie in its rich talent pool and collaborative research environment."



Startups, Scaleups and Commercial Activity

Building what matters

5. Startups, Scaleups and Commercial Activity

The UK's cultivated meat landscape, though smaller than that of the US or Asia, features a diverse mix of startups and scaleups tackling various parts of the value chain. In this section, we profile key companies and initiatives – from those developing end-products to those supplying enabling technologies – and highlight commercial progress to date. A special focus is given to **Quest** as a case study of a UK venture addressing critical industry bottlenecks. We also touch on how UK startups are positioning themselves globally and any early revenue or partnership activities (e.g. pilot product launches, joint ventures).

Pioneering Startups and Their Niches:

- **Ivy Farm Technologies (Oxford)**: Founded in 2019 out of Oxford University, Ivy Farm aims to produce cultivated pork (initially mince for sausages, meatballs, etc.). Ivy Farm made headlines by opening **Europe's largest cultivated meat pilot plant** in 2022 – an 18,000 sq. ft facility with a 600 L bioreactor, capable of ~2.8 tonnes/year production. They have raised over $30 million in funding and received UK government grants. Ivy Farm's strategy is to achieve regulatory approval in the UK by around 2025 and launch products like cultivated pork sausages shortly after. They have publicly targeted a commercial launch by 2025 (likely contingent on FSA novel foods clearance). Ivy Farm also commissioned a report with Oxford Economics projecting the UK cultivated meat industry could reach **$1.7 billion by 2030, supporting 16,500 jobs** – indicating their ambition to play a leading role. In terms of tech, Ivy Farm uses a hybrid approach of proliferating muscle cells in bioreactors and then combining them with plant proteins for structure. Their pilot plant's emphasis on sustainability (solar panels, etc.) and an innovation kitchen for recipe development shows they are preparing not just to grow cells but to create a consumer-ready food with chefs involved. Ivy Farm exemplifies a full-stack cultivated meat startup: doing everything from cell culture R&D to final product formulation in-house..

- **Uncommon* (London/Cambridge)**: Formerly known as HigherSteaks, Uncommon* is also a startup focusing on cultivated pork, especially structured products like bacon. Co-founded by a Cambridge-trained scientist, it has received investment from international VCs and the UK's Agronomics. Uncommon* has developed both muscle and fat from induced pluripotent stem cells (IPSCs), touting that they can create fat marbling for bacon. They did a cooking demo of the UK's first cultivated bacon rasher in 2021 (a small-scale prototype). Uncommon's approach leans on cutting-edge stem cell tech, but they are likely still in pilot lab scale. They benefit from Cambridge's biotech network and have partnerships (e.g. with Bits x Bites in China for future market entry). Uncommon's journey highlights the startup path of early prototyping to lure investors, with the heavy lifting of scaling yet to come.

- **Hoxton Farms (London)**: Differentiating itself from the meat crowd, Hoxton Farms focuses on **cultivated fat** as a B2B ingredient. Recognising that fat is what gives meat much of its flavour, Hoxton's thesis is that the fastest way to improve plant-based meats (and hybrid products) is to supply clean, cultured animal fat to replace palm oil or coconut fat currently used. Founded by mathematicians-turned-entrepreneurs, Hoxton Farms uses computational models to optimise growth media and bioprocess for fat cells. They've raised several million pounds and are building a pilot facility in London. By selling cultured fat as an ingredient, they can enter the market without needing to develop whole consumer products or get over the "lab-grown meat" psychological hurdle (fat can be up to 10-20% of a sausage by weight, so even if the rest is plant-based, it dramatically improves taste).

** no longer trading*

Hoxton has signalled partnerships with existing meat alternative brands to incorporate their fat once approved. This niche strategy might allow revenue generation sooner since the regulatory path for using cultured fat as a novel food ingredient might be slightly simpler than a standalone meat product (though still requires approval). It also leverages the UK's strong food tech sector in London and could integrate with the plant-based manufacturing already happening (several plant-based meat companies operate in the UK and could be customers).

- **CellulaRevolution* (Newcastle)**: A spin-out from Newcastle University, CellulaRevolution* tackles one of the hardest problems: continuous cell culture. Their technology, a peptide-coated surface in a flow bioreactor, allows cells to grow adherently and then detach continuously, rather than in batch. Initially targeting pharma cells, they realised the application for food – continuous processes could vastly improve efficiency and reduce downtime. They secured seed funding and partnerships in the cultivated meat supply chain. This is an example of an enabling tech startup, which might not produce meat itself but sells bioprocess hardware or tech to cultivated meat companies. The UK seems to excel at these picks-and-shovels ventures.

- **Multus Biotechnology (London)**: Multus is a **culture media specialist**, founded by graduates of Imperial College. Multus uses a combination of AI and high-throughput screening to formulate inexpensive media formulations (replacing foetal bovine serum and other costly reagents with food-grade components). They are also building manufacturing capability for these media. Multus received notable funding (including from the UK government's InnovateUK) and in 2024 opened a commercial-scale serum-free growth media production facility – one of the first of its kind – in the UK. This facility can supply cultivated meat startups in the UK and abroad with the critical "feed" for their cell cultures, at much lower cost than buying pharmaceutical-grade media. Multus's success is crucial; media often accounts for 50–80% of production cost at scale, so a local supplier that slashes costs and scales volume is a huge asset. Their partnership with Quest (next) underscores how UK firms are collaborating to build an integrated value chain.

** no longer trading*

> *"Plant-based meat companies operating in the UK and could be customers."*

Case Study – Quest: *Enabling Affordability and Scale-up for Cultivated Meat*

Quest is a shining example of a UK startup addressing the **practical bottlenecks** of cultivated meat production. Founded in 2020–21 by a team of stem cell bioprocessing experts, Quest deliberately positioned itself as an enabler rather than a competitor to cultivated meat producers. Their mission is encapsulated in their tagline: "developing ingredients that will make cultivated meat affordable, scalable and sustainable". Quest identified two of the biggest barriers facing the industry: **(1) the removal of foetal bovine serum (FBS)** – an expensive and ethically problematic growth medium – and **(2) adequate scaffolding for cell growth and tissue formation** at scale. To tackle these, Quest is developing proprietary solutions on both fronts:

- **License-free Primary Cell Lines**: Quest offers high-quality primary muscle and fat cell lines from livestock (cow, pig, and even water buffalo), which they provide in kits to other companies. These cells come from various breeds (e.g. British Blue cattle) to suit different needs. By making cell lines available *without onerous licensing fees*, Quest lowers a barrier for startups or researchers who need reliable starting material. This approach also speeds up R&D because not every company has to re-invent the wheel in isolating and testing cell strains. It is akin to providing the "seeds" for the industry. Each vial comes with a certificate of analysis and a culture protocol – showing Quest's emphasis on being a turnkey solution provider. This not only generates revenue for Quest early (selling cell vials), but also potentially sets a standard if their cells become widely adopted.

- **Serum-Free Media & Microcarrier Replacements**: Quest is advancing a **patent-pending multi-format ingredients platform**, which includes a food-safe FBS replacement and edible microcarriers. In traditional cell culture, microcarriers (tiny beads) are used in bioreactors for cells to attach to; however, most are made of materials not edible (plastic or coated beads), requiring removal of cells from them. Quest's idea is to create microcarriers that are made of edible material (some kind of plant-derived polymer or gelatine) so they can remain in the final meat, becoming part of the structure – thus simplifying the process (no cell harvesting step). They have shown prototypes of such microcarriers (e.g. in early 2025, Quest publicly tasted a prototype microcarrier made from edible materials, as noted in industry news). Likewise, their **low-cost serum replacement** is aimed to be a supplement made from food industry byproducts or algal/plant extracts that provides the growth factors needed, at a fraction of FBS cost. This is crucial because even in 2022, FBS could cost hundreds of dollars per Litre; replacing it could cut media cost by 80–90%. Quest indicates these products are "coming soon" on their site and has been testing them in bioreactors.

- **Collaboration & Validation**: Recognising the complex nature of scaling, Quest actively partners with others. In **January 2024, Quest and fellow UK startup Multus announced a £1 million InnovateUK-funded project** with UCL to develop "CULT-GRO" – a combined low-cost growth media and edible scaffold system. In this project, Quest screens various formulations in stirred bioreactors at its Birmingham facility, while UCL validates them in more advanced setups. The partnership merges Quest's microcarrier and nutrient innovations with Multus's media

> *"By making cell lines available without onerous licensing fees, Quest lowers a barrier for startups or researchers who need reliable starting material."*

expertise. The aim is to deliver a system that **"enables cultivated meat production scale-up at a fraction of the current cost."**. By mid-2025, this project is presumably yielding results, positioning Quest and partners to offer an integrated kit (cell lines + media + scaffold) for anyone trying to cultivate meat at pilot scale.

- **Team and Expertise**: Quest's founding team includes seasoned biotech entrepreneurs and academics – e.g. Prof. Petra Hanga (CSO, an academic in regenerative medicine), Dr. Ivan Wall (CEO, bioprocessing expert), Dr. John Sinden (co-founder, previously founded a stem cell therapy company). This deep domain experience in cell culture and biomanufacturing gives Quest credibility. Unlike many foodtech startups founded by generalists, Quest is heavy on PhD and industry veterans, which helps in solving technical problems efficiently and partnering with academia (e.g. their UCL ties). It is also notable that one founder (Ivan Wall) is involved with CARMA hub, and another (Petra Hanga) is affiliated with UCL – indicating strong alignment with the UK's academic network.

- **Commercial Traction**: While Quest is not directly making a consumer product, it already has customers for its enabling products: cultivated meat companies globally can purchase their cell lines or collaborate on media testing. Quest has engaged companies in the EU, North America, and Asia who are keen to reduce costs. Also, Quest benefits from non-dilutive funding (grants) as seen with the InnovateUK award. As cultivated meat firms start pilot runs, Quest's ready-to-use cell banks and cost-saving ingredients could become in high demand. For example, an overseas company might license Quest's cell line to avoid dealing with EU's genetic resource regulations or to get a cell type with better growth. Quest's emphasis on being "license-free" for primary cells is a strategic decision that lowers the upfront cost to their clients – they might instead monetise through volume sales of cells or support services, rather than royalty, making it attractive to early industry players.

Other Noteworthy Players:

- **Roslin Technologies (Edinburgh)**: As mentioned, Roslin is providing cell lines and has a unique angle via pet food. Roslin spun out Good Dog Food, a startup focused on cultivated meat for pet consumption (since pets do not mind if their meat is grown, and owners might pay a premium for ethical pet food). Good Dog Food (trading as Meatly) achieved the world's first regulatory-approved cultivated meat sale in pet food in 2025 in the UK. This is a commercial milestone: **Meatly's cultivated chicken dog treat** went on sale at Pets at Home stores in 2025, marking the UK's (and Europe's) first cultivated meat sales (albeit not for humans). Roslin and partners behind Meatly plan to use this as a stepping stone and eventually adapt the tech for human food. It is also a clever way to generate revenue sooner – affluent pet owners can be an entry market. The success of Meatly shows UK startups finding creative beachheads to commercialise ("pets today, people tomorrow") and highlights the supportive stance of UK regulators toward innovation in food.

- **Biotech Foods UK operations / JBS**: With JBS (the Brazilian meat giant) acquiring BioTech Foods in Spain and planning a R&D centre in Brazil, it's worth noting JBS also established a presence in the UK through acquiring **Vivera** (a plant-based company) and possibly will look at cell-ag research ties in Europe. While not a UK startup, if JBS or other multinationals decide to set up cultivated meat R&D in the

> *"Meatly achieved the world's first regulatory-approved cultivated meat sale in pet food in 2025 in the UK."*

UK (to tap the talent or regulatory environment), that could change the competitive dynamic. As of now, no large incumbent meat company has a cultivated meat lab in the UK that we know of, but it's an area to watch.

- **Academic Spin-offs and Projects**: Some early-stage spin-offs include *Cellular Agriculture Ltd* (a Bath spin-off exploring cultured meat tech, merged into other entities now) and ongoing projects like *New Harvest-supported research at King's College London on serum-free media*. These are seeds that could sprout into new startups or be absorbed by existing ones.

Commercial Activity and Milestones: On the commercial front, beyond R&D, the UK's cultivated meat sector is gradually building an *ecosystem of partnerships and small-scale product demos*. Key milestones to date include:

- *Tastings and Prototypes*: Besides Ivy Farm's internal tastings, in June 2022 a London restaurant (in collaboration with a US company) hosted a private tasting of cultivated meat for journalists – indicating public interest. The UK public has not yet been offered cultivated meat to purchase (as of 2025, since no human approval), but companies are engaging chefs and media to build anticipation.

- *Regulatory Engagement*: Several UK companies have either submitted or are preparing **Novel Foods dossiers** to the FSA. Likely candidates are Ivy Farm (for pork mince) and a collaboration like Aleph Farms with a UK partner for steak, etc. The FSA sandbox mentioned fast-tracking two products – these could very well be Ivy Farm's pork mince and an import like Upside's chicken or Aleph's steak, as test cases. The outcome of these will shape commercial launch timelines.

- *Foreign Market Focus*: Some UK startups are eyeing overseas markets for first launch. For example, if the EU remains slow but Singapore is open, a UK company might partner to launch in Singapore earlier (like how Israel's SuperMeat opened a tasting restaurant there). The UK's Quest/Multus partnership might yield tech that can be sold worldwide even before UK domestic product sales ramp up.

- *Industry Alliances*: UK startups often collaborate under initiatives like the **Cultivated Meat Collaboration** (recently, 2023 saw UK companies join a European alliance to share regulatory knowledge and do joint lobbying). This collective approach helps smaller firms have a bigger voice.

In summary, the UK's cultivated meat startup scene is vibrant and mission-driven, if not yet at scale. Companies like **Quest, Multus**, and **Hoxton Farms** illustrate a focus on enabling technologies and B2B inputs – a smart play that builds the supply chain and can generate income by serving the global market of cultivated meat producers. Meanwhile, Ivy Farm, Uncommon*, and others are pushing the envelope to bring actual cultivated meat products (or hybrids) to consumers, positioning the UK as a source of premium sustainable meat. Early commercial wins like the pet food approval show that UK innovators can navigate regulation effectively. The next few years should see these startups either scaling up domestically – building pilot plants with tens of thousands of litres capacity – or partnering with larger entities for manufacturing and distribution.

** no longer trading*

"The UK's cultivated meat startup scene is vibrant and mission-driven."

5. Startups, Scaleups and Commercial Activity

For investors and observers, the takeaway is that **the UK punches above its weight in expertise and innovation**, and with the right support, its startups could capture significant value in the emerging global supply chain of cultivated meat. The subsequent section on investment and the capital landscape will delve into how these startups are funded and which strategic investors are participating, as well as how incumbent food industry players (in the UK and beyond) are engaging with this sector's growth.

5

Building what matters

“For investors and observers, the takeaway is that the UK punches above its weight.”

6

Strategic Investors and Capital Landscape

Building what matters

6. Strategic Investors and Capital Landscape

The cultivated meat sector's advancement in the UK (and globally) depends not only on entrepreneurial science, but critically on the **capital and strategic partnerships** that fuel growth. This section examines who is financing the cultivated meat revolution – from venture capital funds and angel investors to corporate strategic investors and public funding – and how the UK's capital landscape compares internationally. It also looks at incumbents (big food and meat companies) and their moves, since these established players can be kingmakers in a nascent industry through investments, acquisitions, or lobbying. We identify trends such as the recent contraction in venture funding, the emergence of specialised alt-protein investors, and the increasing role of government and non-traditional capital in bridging funding gaps for scale-up.

Venture Capital and Alt-Protein Funds: In the 2016–2021 period, much of the funding for cultivated meat came from mission-aligned venture capital – often new funds explicitly focusing on food tech or climate tech. The UK has been home to some of these early movers:

- **Agronomics Ltd**: A pioneer, Agronomics is a UK-listed investment firm (traded on the LSE AIM) founded by Jim Mellon. It exclusively invests in cellular agriculture and has built a portfolio of 20+ startups globally, including notable names like **Mosa Meat, Meatable, BlueNalu, VitroLabs**, and also several UK companies (Meaty – the pet food venture, Hoxton Farms, etc.). Agronomics often co-invests alongside international VCs, providing early capital and follow-ons. It has been instrumental in funding rounds for Roslin Tech, Meatable, and others. Agronomics offers an example of how public market investors can access the field (its shares let retail investors bet on cell-ag). By April 2025, Agronomics reported an IRR >20% on its portfolio so far (on paper) but also acknowledged the need for patience. It has called out that 2025–27 will be telling, as companies must either hit milestones orconsolidate. Agronomics sometimes also provides bridging funds to companies struggling to raise in the current environment (it topped up some investments in 2023–24 when other VC money slowed).

- **Synthesis Capital**: A London-based fund launched in 2022, Synthesis raised $300 million with a mandate for alternative proteins (cultivated, plant, fermentation). Synthesis has invested in **Upside Foods, Perfect Day** (fermentation dairy) and others, and likely some UK startups. Their presence brings big-ticket financing capability (they can lead Series B/C rounds). Synthesis sees alt-proteins as a **convergence of food and biotech**, matching the UK's strength in both.

- **CPT Capital**: The venture arm of Jeremy Coller (a notable investor and advocate for sustainable protein), CPT Capital is London-based and was one of the earliest backers of Impossible Foods, Beyond Meat, and Upside Foods. They remain active and have stakes in cell-ag companies around the world. CPT's focus is cross-alternative proteins, not just cultivated, but they have deep sector knowledge and often network their portfolio companies together (including facilitating partnerships with food conglomerates).

- **Global VCs with UK reach**: Many global foodtech or climate funds have looked at UK deals or have partners in Europe. Examples: **IndieBio/SOSV** (accelerator which funded early cell-ag startups, though none from UK yet, it's US/Ireland based), **Blue Horizon** (Swiss-based, big alt-protein investor, has funded UK's Hoxton Farms and others), **Lever VC** (US/China, did early Hoxton Farms), **KBW Ventures** (Prince Khaled's fund, invested in Meatable, perhaps others). As UK startups progress to larger raises, these international funds often co-invest with local ones.

"Often new funds explicitly focus on food tech or climate tech."

6. Strategic Investors and Capital Landscape

Funding Trends: As noted, venture funding peaked around 2021 and then declined. The UK felt this too: some planned large raises were downsized or delayed. For instance, rumours of Uncommon* seeking a big Series A took longer. **Downward valuation pressure** is causing some startups to raise convertible notes or focus on grants rather than equity. The Good Food Institute bluntly noted that "private funding has almost dried up" for cultivated meat in late 2024, with total sector funding in 2024 down ~90% from 2021's high. This means **UK startups must be capital-efficient or find alternative financing**. Encouragingly, the UK government and aligned entities are stepping in more: Innovate UK competitions, as well as the new Engineering Biology Transition Fund (which allocated part of £20m to cellular agriculture companies in 2023), provide grants.

Blended Finance & Project Funding: One emerging theme is the need for project finance to build production facilities. Venture capital is not designed to fund multi-hundred-million-dollar factories (that's more the realm of infrastructure or corporate capex). For cultivated meat, the first commercial plants (1000+ ton/year) are high risk and unlikely to secure bank loans without guarantees. This is where **public-private partnerships** could come in. The GFI's 2024 report "Funding the Build" suggests options: equipment leasing models, government-backed loans, or even sovereign wealth funds investing for strategic reasons. We have not yet seen this fully in the UK, but seeds are there: the **UK's National Food Strategy** (2021) recommended investing £125m in alt-protein innovation, and by 2024 about **£75m public funds** had been committed, ~60% of that goal. The majority went to research centres (NAPIC, CARMA) and some company grants. In the future, the UK's new infrastructure bank or Net Zero Innovation Portfolio might consider funding a large-scale BioManufacturing plant that could produce cultivated meat on a contract basis for multiple companies (shared infrastructure model).

This is speculative, but it aligns with the idea of de-risking first-of-a-kind facilities with public money.

Corporate Strategic Investors: Big food and meat companies often invest in emerging food tech both to hedge and to integrate new tech into their supply chains. Globally, nearly all top meat companies have made a move:

- **JBS (Brazil)**: As discussed, acquired BioTech Foods (Spain), and is investing $100M in cultivated meat (plant in Spain, research centre in Brazil). They have not specifically invested in UK companies, but their aggressive push means they will be a competitor or partner in any market.
- **Tyson Foods (US)**: Initially invested in Upside and Israel's Future Meat; they divested some of those later, but recently Tyson's venture arm signalled renewed interest especially if products near market. Another US meat giant, Cargill, invested in Aleph Farms (cultivated steak) and cultured seafood (Upside's cell-based fish division).
- **European Meat Companies**: Not as forefront, but there are moves: e.g. PHW Group (top German poultry firm) invested in SuperMeat (Israel). In the UK, legacy meat processors (e.g. 2 Sisters, Cranswick) have been a bit quieter publicly. Cranswick did partner with a Finnish cultured fat company (Solar Foods) in an EU project, showing curiosity.

** no longer trading*

"Big food and meat companies often invest in emerging food tech."

6. Strategic Investors and Capital Landscape

- **Food FMCGs**: Some global food manufacturers are dipping in – **Nestlé** announced in 2022 it was evaluating hybrid products with cultivated meat (it partnered with Israel's Future Meat for a lab prototype of cultivated chicken breast with veggie protein). Nestlé could eventually license tech or co-develop with startups to create products under its brands. Unilever has an alt-protein division which so far focused on plant-based (e.g. bought The Vegetarian Butcher) but is surely monitoring cell-ag. If big CPG companies start investing or partnering, it can massively accelerate commercialisation via their scale and distribution.

- **Investments in UK firms**: To date, most UK cultivated startups' cap tables are filled with VCs and angel groups, rather than strategic corporates. However, **some strategic interest is emerging**: e.g. **Mitsubishi Corporation** (the Japanese conglomerate) invested in UK's Multus Media in 2022, with an eye on securing future media supply for Japan's foray into cell-ag. **Molson Coors** (via a venture partnership) invested in UK's meat-alternative companies (not sure if any cultivated, but they invested in fermented protein). As UK startups progress, we might see tie-ups like a major UK supermarket chain investing or partnering for trials. In 2023, supermarket

  Waitrose's CEO publicly mentioned they are watching cultivated meat and would introduce it when approved, with exclusive partnerships.

Public Markets and Exits: The first cultivated meat companies may pursue IPOs or acquisitions in the coming years. Globally, a few cell-ag related companies have gone public via SPACs (e.g. MeaTech/ Steakholder Foods on Nasdaq, which has not performed well). The UK's markets (like AIM) could be an exit route – Agronomics is already public; one could envision Ivy Farm or others listing if they want to raise large sums for scale. However, given current market scepticism, many will stay private longer or look for corporate M&A. A plausible scenario: a big meat company acquires a leading startup to integrate the tech (e.g. JBS or Tyson buying one of the top startups). For UK companies, being acquired by an international firm is possible – which might be good for founders/investors but could mean technology leaves UK control. Policymakers may have an interest in preventing a "brain drain" in this strategic sector, by ensuring UK firms have enough domestic capital to grow independently.

Role of Government and Policy Incentives: The UK government, beyond grants, could incentivise investment through **tax breaks or procurement**. One idea floated is R&D tax credits specifically boosted for alt-protein R&D or adding alternative proteins to the remit of green financing (e.g. including it in the definition of sustainable investments for ESG funds). Also, if the UK were to announce a future carbon tax on high-emission foods or stronger sustainability disclosure for food companies, it indirectly makes cultivated meat more attractive to invest in. To date, the UK hasn't used such levers, but the National Food Strategy did hint at supporting sustainable protein.

> *"The UK government could incentivise investment through tax breaks or procurement."*

6. Strategic Investors and Capital Landscape

Investor Challenges: An underlying challenge for investors (LPs and VCs alike) is balancing long-term vision with short-term results. The timeline to meaningful revenue in cultivated meat is longer than many initially hoped. This means some earlier investors might lose patience or face pressure from their own fund cycles. Indeed, the GFI noted companies that cannot get funding will **"downsize, consolidate, or close"**. Already, we have seen signs of consolidation globally: e.g. UPSIDE Foods acquiring assets of the defunct cultured seafood startup Cultured Decadence, or BioFood Systems (UK small startup) merging with another. In the UK, there have not been major casualties yet, but if the funding climate stays tight, some of the 8-10 cultivated meat startups might merge or pivot to other tech (like some might focus on high-value pharma applications to survive). For investors, picking winners is tough with so many technical unknowns. This has led to a spread approach (invest in a basket). But now that basket funding is scarce, investors are focusing on those who have a clear differentiated tech or path to market.

In the UK context, ventures like **Quest/Multus** that provide enabling tech appealing to the whole sector may be safer bets than those which will burn cash marketing their own product. Also, pet food and B2B plays (lower regulatory bar, easier early revenue) might see more investment interest in the short term. For instance, after Meatly's success, one could see investors funding expansion of cultivated pet food – a niche but real market.

Global Capital Distribution: It is instructive to note how global investment is distributed. The GFI's data show North America has usually received ~50%+ of cultivated meat investment, Asia ~30%, Europe ~15-20%. Within Europe, the UK, and Netherlands lead in number of companies. In 2024, Europe's alt-protein investments actually picked up even as global fell (due to some big plant-based raises), but cultivated meat specifically in Europe was a small portion (Mosa Meat's €40M was a highlight). The UK had single-digit millions in disclosed cultivated raises in 2024 (Quest's grants, Hoxton's $10M Series A), indicating reliance on non-dilutive funds.

The Path Forward – Strategic Alignment: We anticipate that strategic investors (corporates, sovereign funds) will dominate the next phase of funding. For example, **Saudi Arabia's NEOM fund** invested in cellular agriculture companies as they plan futuristic cities (food security angle). Similarly, **Singapore's state funds (Temasek)** have invested heavily in alt-proteins globally (they back Upside, etc.), aligning with Singapore's food strategy. The UK could attract such capital if it demonstrates a welcoming environment (e.g. if the UK approves products sooner than the EU, one might see Singapore or Middle East funds channelling money into UK ventures to leverage that regulatory advantage).

Additionally, UK corporates like **Tesco or M&S** might eventually invest in supply chain innovation to meet sustainability pledges – for instance, investing in a cultivated meat supplier to secure future product lines exclusively. This has not happened yet, but Tesco has partnered with Beyond Meat (plant-based) for exclusive products; a similar model could emerge with cell-based meat when ready.

"Saudi Arabia's NEOM fund invested in cellular agriculture companies as they plan futuristic cities."

6. Strategic Investors and Capital Landscape

Conclusion (Capital Landscape): In summary, the cultivated meat capital landscape is in a transitional phase. The UK stands to benefit from its strong start-up base but must navigate a period of tighter capital availability. Key strategies include leveraging **public funding** to catalyse private investment (as seen with InnovateUK grants drawing matching VC dollars in Quest's project), engaging **strategic corporate partners** early for mentorship and possibly off-take agreements (which can make raising money easier if you have a purchase agreement in hand), and exploring **innovative financing** (like consortium funding for shared facilities). The UK's investor community is small but tight-knit; continued government signalling that alt-proteins are a priority can encourage more generalist VCs and institutions to participate. Notably, in early 2025 the UK's *Net Zero Technology Investment* list included alternative proteins as a category, which might unlock climate-tech funding streams.

For LPs and GPs, the implication is that while short-term returns may be elusive, the *long-term value proposition remains intact*. The underlying drivers (climate, food security) are not going away; if anything, they intensify. So, we expect that as macro conditions stabilise, capital will return to this sector with more disciplined expectations. In the meantime, bridging the gap requires creativity and collaboration between startups, corporates, government, and the financial community. The next section on incumbents will continue this thread by exploring how existing value chain leaders are responding, and how cultivated meat might integrate or disrupt the current food industry structure.

7

Incumbents and Value Chain Leaders

Building what matters

7. Incumbents and Value Chain Leaders

Cultivated meat is an emergent technology that does not exist in isolation – it must interface with the **incumbent players of the food system**. These include the large meat and poultry companies, ingredient suppliers, equipment manufacturers, retailers, and other value chain leaders. Some incumbents may view cell-based meat as a threat to their current business, while others see an opportunity and are actively investing or adapting. This section analyses the stance and actions of incumbents, especially in the UK context, and examines how the broader value chain (from feedstock inputs to distribution) might reconfigure if cultivated meat gains traction. It also discusses strategies for incumbents: e.g., meat companies diversifying into cultivated meat, or farmers finding new roles in a cellular agriculture world.

Meat Industry Giants – Adaptation or Opposition? The traditional meat sector is not monolithic in its response. We see a split: **forward-looking firms hedge their bets by investing in cultivated or hybrid products**, whereas others (often via trade lobbies) resist by pushing for protectionist measures or negative framing.

- **International Meat Corporations**: As previously mentioned, global companies like JBS, Tyson, and Cargill are hedging by investing in or partnering with cultivated meat ventures. For example, JBS's construction of a 1,000 ton cultivated beef plant is a striking commitment – it implies JBS envisions a future where a portion of their product mix could be cell-derived. They have publicly stated cultivated protein can help "stabilise food security" and reduce supply chain volatility. Similarly, Tyson's early venture bets and Cargill's involvement (Cargill supplies inputs like cell nutrients to Aleph Farms) suggest a recognition that ignoring the trend could be risky if consumer demand shifts. These companies bring expertise in **scaling, cost-down, and distribution**, which could accelerate commercialisation if they fully engage. However, they also maintain core investments in conventional meat, which will be cash cows for years.

- **European and UK Meat Producers**: In the UK, major meat producers (like **ABP UK, Moy Park, Cranswick, Pilgrim's UK**) have not made public moves in cultivated meat as of 2025. However, some have dipped into plant-based (Cranswick launched a plant protein range). It is possible they are internally researching cell-ag or waiting for clearer signals. UK industry groups like the **National Farmers' Union (NFU)** and **British Meat Processors Association (BMPA)** have so far not been overtly hostile but are cautious. The NFU tends to emphasise the quality and sustainability improvements of British farming and might lobby for labelling restrictions (to ensure "meat" means slaughtered meat, for example). A sign of opposition: in the EU, the Italian government's proposed ban on cultivated meat (2023) had support from farming lobbies who fear competition and loss of cultural heritage. Some UK voices echo this – e.g., certain MPs have raised questions if "lab meat" might undermine farmers or whether it's truly safe. That said, the UK's approach has been more open than Italy's; rather than bans, the UK established the **Cultivated Meat & Farmers study** to engage farmers proactively. This study's early results show farmers are split – some see it as threat, others as potential (like providing feedstock inputs or creating a premium for traditional meat).

- **Farmers and Supply Chain Roles**: If meat is grown from cells, what becomes of farmers and feed producers? This is a crucial incumbency question. One optimistic scenario is that farmers could pivot to grow **inputs for cell media** – e.g. sugars, amino acids, or plant hydrolysates – becoming suppliers to cultured meat factories instead of raising animals. For instance, a farmer cooperative might grow peas or barley that are processed into protein hydrolysates to feed bioreactors (some media formulations use plant peptones as a nutrient source). Another role: farmers could host bioreactors on farms, using their land and renewable energy to produce cultivated meat onsite (especially if modular production units become feasible).

7

Building what matters

> *"Farmers could host bioreactors on farms, using their land and renewable energy to produce cultivated meat onsite."*

The Cultured Meat & Farmers project in the UK is mapping how different farming sectors could be affected – dairy farmers might adapt to cultivate milk proteins or even muscle cells using their know-how in animal husbandry reframed. Some farmers in the focus groups imagined marketing their pasture-raised meat as the "real deal" at a premium if cheap cultivated meat floods the low-end market, while others thought of supplying raw materials (like growth factors derived from plants). It's clear that without inclusion, farmers might join opposition; with inclusion, they could become allies. The UK government's collaborative approach (forums, pump-priming projects involving Royal Agricultural University, etc.) suggests a desire to avoid a zero-sum scenario and instead find a "just transition" for agriculture.

Ingredient and Input Suppliers: Cultivated meat production will rely on a new **value chain of inputs**: cell culture media components (amino acids, vitamins, growth factors), scaffolding materials, bioreactor equipment, sensors, etc. Many of these are made by companies currently serving pharma or food:

- **Life Sciences Companies**: Firms like Thermo Fisher, Merck KGaA (Sigma-Aldrich), and Sartorius provide media ingredients and bioprocess equipment. There is evidence they are eyeing the food market: e.g., **Thermo Fisher** in 2022 launched a line of animal-component-free cell culture media "for food tech" – repackaging some products for cultivated meat startups, at lower margins. **Sartorius** (bioreactor manufacturer) has published thought leadership on cultivated meat and is adapting some of its bioreactors for use by food startups. As volume demand grows, these suppliers will ramp up production of food-grade components in bulk, which should drive costs down further due to economies of scale (shifting from small pharma batches to large food batches). Their challenge is maintaining quality standards while dramatically cutting costs. For example, a growth factor protein that costs $1000/mg for pharma might need to be produced via fermentation at pennies per mg for food. Companies like **Novozymes** and **DSM** (enzyme and biotech giants) are well positioned to mass-produce growth factors or essential proteins for media using fermentation.

- **Food Ingredient Giants**: Traditional ingredient companies such as **Tate & Lyle (UK), DSM-Firmenich, Kerry Group**, and **Givaudan** could play roles in flavouring or texturising cultivated meat products. For instance, Givaudan (flavour & fragrance leader) has already partnered with Bühler and Migros to create **The Cultured Hub** in Switzerland, a pilot plant to help startups scale up and add flavour expertise. This indicates that big ingredient firms see opportunity in supplying the cultivated meat sector (e.g., enhancing taste of bland cultured chicken, or providing binding agents for hybrid products). British ingredient firms might similarly adapt – e.g., **Croda International**, known for specialty chemicals, could potentially supply lipids or gelatines for scaffolds.

- **Equipment Manufacturers**: If cultivated meat scales, there will be demand for **industrial bioreactors far larger than today's** (e.g., 10,000–20,000 L tanks, perhaps even larger in the long run). Companies like ABEC, Cytiva, or even brewery tank manufacturers might fill this need. In the UK, there is expertise in brewing and distilling equipment (some craft brewing tank makers might repurpose to bioreactors). Additionally, new companies like **Ark Biotech (US)** focus on designing cultivated-meat-specific bioreactors (they raised $8M in 2024). UK engineers and manufacturing firms (maybe those in oil & gas or chemical industries) could pivot to making bioprocess hardware given the right incentives.

7

"Big ingredient firms see opportunity in supplying the cultivated meat sector."

7. Incumbents and Value Chain Leaders

Retail and Foodservice Incumbents: Ultimately, cultivated meat must reach consumers through supermarkets, restaurants, etc. How these players behave is crucial:

- **Supermarkets**: UK grocers have been leaders in promoting plant-based foods – e.g., Tesco has a partnership with Beyond Meat and set ambitious targets to boost alt-protein sales by 300%. One can anticipate a similar openness to cultivated meat once it is approved. In fact, in 2020 **Sainsbury's** did a consumer survey about lab-grown meat, and Waitrose's head of innovation has commented that they expect to stock cultivated meat within a couple of years of approval, seeing it as part of offering sustainable choices. Supermarkets might initially introduce it in a limited trial (perhaps one chain pairs with one supplier for an exclusive launch, similar to how M&S in 2019 exclusively sold the first plant-based steak from Vivera). Given UK retailers' influence and their own Net Zero 2040 goals, some may actively support cultivated meat to reduce scope 3 emissions in their supply chain. Conversely, if they sense customer resistance, they may tread carefully (as happened with GMO foods in the UK in 1990s – retailers refused to stock them due to consumer backlash). Retail pricing strategy will matter: if cultivated meat is expensive at first, they might position it as a premium ethical product, not a mass commodity.

- **Restaurant Chains**: Food service could be a primary introduction channel, as it has been in Singapore and the US. In the UK, high-end restaurants or celebrity chefs might serve cultivated meat in tasting menus to generate buzz (e.g., perhaps Heston Blumenthal or similar culinary innovators would be interested). Chain restaurants that have embraced plant-based options (like Gregg's with its vegan sausage roll, or Burger King trailing plant-based outlets) could similarly pilot a cultivated meat dish. Acceptance in restaurants can help break down psychological barriers by having trusted chefs endorse it. It is likely that by late 2020s, some UK restaurants will have limited-time offerings of cultivated meat (sourced from abroad initially if UK production lags).

Logistics and Distribution: If cultivated meat production localises (urban factories), it may shorten the supply chain compared to conventional meat (which involves farms -> slaughterhouses -> processors -> distribution centres). Incumbent meat distributors might adapt to handle both traditional and cultivated products. Cold chain requirements would be similar (cultivated meat will be sold chilled/frozen like regular meat). One potential advantage: cultivated meat production could be more closely matched to demand (less seasonality, no breeding cycles), which might reduce the big gluts and shortages the meat industry grapples with. Incumbents in distribution who adapt to just-in-time production cycles could reduce waste and cost.

Potential Disruption to Byproduct Industries: Conventional meat yields many byproducts (leather from hides, animal feed from bone meal, etc.). If cultivated meat scaled, these industries (leather, pet food made from offal) could be impacted. We already see synergy: if less slaughter, leather supply drops – but startups are making lab-grown leather (like Modern Meadow). Pet food might shift to using cultivated meat (like Meatly does), which if priced right could displace rendered meat meals. Companies in these byproduct sectors might need to repurpose (collagen for scaffolds instead of gelatine desserts, etc.).

7

bappla
Building what matters

"Waitrose's head of innovation has commented that they expect to stock cultivated meat within a couple of years of approval."

7. Incumbents and Value Chain Leaders

Consumer Brands: If cultivated meat becomes a raw material, we may see **new brands** or **line extensions** from incumbents. For example, a well-known sausage brand might launch a "cell-based sausage" line marketed for the climate-conscious. Or fast-moving consumer goods companies (like Nestlé, Unilever) might include cultivated meat as an ingredient in ready meals or canned foods. The brand positioning and marketing will be crucial to acceptance. Incumbent brands can lend familiarity and trust to an unfamiliar product – e.g. if Birds Eye (famous UK frozen food brand) made fish fingers with cultivated fish cells, consumers might accept more readily due to the brand's legacy. On the other hand, missteps by incumbents (like trying to hide the nature of the product) could breed distrust. Transparency and education will be part of brand strategies, with eco-labels highlighting the sustainability.

Regulatory Influence and Lobbying: Incumbents often have strong lobbying power. In the EU, meat lobbies fought to prevent plant-based foods from using terms like "burger" (that attempt largely failed except for "milk" etc.). With cultivated meat, we can expect lobbying on labelling (requiring words like "lab-grown" or forbidding use of just "meat" without qualifier). The UK, being more agile post-Brexit in setting its own rules, could define labelling in a way that balances clarity and marketing. Incumbents in the UK might push for something like "cultivated [animal] protein" labelling to differentiate but still allow the animal's name. Too pejorative a label (e.g. "synthetic meat") could kill consumer interest. Policymakers must manage these influences; given the UK's pro-innovation stance so far, one hopes they lean on science and consumer research rather than purely incumbent interest. Notably, a 2021 FSA survey found most UK participants expect these products to be **"regulated and clearly labelled"** – so fulfilling that will be key to legitimacy.

Value Chain Evolution – A Cooperative Model? One interesting possibility is incumbents and startups working together to integrate the value chain. For instance, a big meat company might provide its food safety and processing expertise to cultivated meat startups (ensuring the final product meets texture and taste standards), while the startup provides the base cell-grown material. The outcome could be a co-branded product: e.g., "Cultivated Beef Burgers – produced by [BigMeatCo] in partnership with [TechStartup]". This kind of model can accelerate market entry (startups get scale and distribution; incumbents get innovation and a new product line). Early signs include the partnership in Switzerland where a retail giant (Migros) joined with tech companies to form The Cultured Hub – showing an incumbent taking initiative to facilitate production. The UK might see something akin: perhaps a large food processor like 2 Sisters Food Group could allocate a portion of a plant to a cultivated meat line if a startup provides the bioreactors.

7

bappla
Building what matters

"The UK, being more agile post-Brexit in setting its own rules."

7. Incumbents and Value Chain Leaders

Summary: Incumbents across the value chain are gradually moving from curiosity to engagement. Those who treat cultivated meat as an opportunity to innovate (or at least diversify) are likely to remain relevant if consumer adoption grows. Those who fight it risk reputational issues (appearing anti-environment) or missing out if consumer preferences change in the long term. The UK is fostering a collaborative environment – involving farmers in discussions, funding consortia that include both academia and industry, etc. Over the next decade, we expect to see more **hybrid structures**: traditional meat companies launching their own cultivated lines, farmers co-owning cell-ag facilities, and suppliers modifying products for the new industry.

There will undoubtedly be friction: as cultivated meat potentially displaces some demand for conventional meat, especially for lower-grade meat used in processed products (mince, nuggets), some incumbents could see shrinking markets. In a worst-case scenario, incumbents could entrench (like tobacco companies historically did against new regulations) and try to use politics to slow down the new industry. In a best-case scenario, many incumbents transform – e.g., a meat company becomes a "protein company" agnostic to source, farmers become "energy and biomass producers" fuelling both animals and bioreactors, and consumers get more choices without an adversarial dynamic.

The reality will be in between; but importantly, in the UK context, maintaining dialogue between innovators and incumbents is vital. The inclusive approach (workshops, joint projects) cited in UK sources is a positive sign. As cultivated meat edges closer to market, incumbents that lead (rather than follow) could even drive standards and public trust by lending their familiar names and rigorous quality control to these new products. The next section on risks and barriers will look at some of these dynamics from a risk perspective – including incumbent resistance as one of the potential market barriers – and other systemic challenges that need addressing.

"In the UK context, maintaining dialogue between innovators and incumbents is vital."

8

Risks, Barriers, and Systemic Challenges

Building what matters

8. Risks, Barriers, and Systemic Challenges

Despite remarkable progress, the cultivated meat sector faces a range of **risks and barriers** that could impede its growth. These challenges are multi-faceted – technological, regulatory, market-related, and human capital/talent issues – and many are interrelated. Over the next decade, stakeholders must navigate these to avoid a scenario where cultivated meat fails to deliver on its promise. Below we analyse the key risks and barriers, structured by category, and discuss their implications, particularly in the UK context.

1. Technological and Production Challenges:

- **Scale-Up and Manufacturing Risk**: The most pivotal barrier is the engineering challenge of scaling production. Cultivated meat requires growing trillions of cells in enormous bioreactors with precise control. No food industry precedent exists for cell culture at the scale and low cost needed. Current pilot facilities (like Ivy Farm's 600 L reactor) are tiny compared to what is needed for mass market. Estimates suggest a single facility would need of about **250,000 L capacity** to produce a mere 1% of the UK's meat consumption – and globally, to replace even 10% of meat, thousands of large bioreactors would be required. Achieving uniform cell growth and preventing contamination at that scale is unproven. The **risk** is that unforeseen bottlenecks (oxygen transfer limits in large tanks, shear stress damage to cells, etc.) make it extremely hard to ever hit cost parity. Indeed, a 2024 review highlighted that cost estimates still range wildly (some models say $16/kg possible, others insist costs could remain >$1000/kg), reflecting uncertainty. If engineering hurdles are not overcome, cultivated meat could remain a niche craft operation rather than a commodity. Mitigation: The UK's CARMA hub and similar efforts globally are directly addressing these scale issues – e.g., developing better bioreactor designs, continuous production methods, and automation to manage large facilities. It will require iterative learning, similar to how semiconductor fabs or car assembly lines matured. There is also a push for **decentralised smaller-scale production** (modular bioreactors deployed widely) versus a few mega-factories, but small units sacrifice economies of scale. The UK might explore which model suits it (e.g., a network of mid-sized regional production units might align with existing food processing sites).

- **Cost of Inputs (Growth Media)**: As extensively noted, the expensive growth medium is a major barrier. Even with advances like $0.63/L media, when you multiply by thousands of litres for big reactors, media costs remain significant. Today's cheapest estimates (like $2–$5 per Litre) still mean tens of dollars per kg of biomass just for media. And that's optimistic; if any component (like growth factors) still needs pharmaceutical-like manufacturing, costs blow up. The **risk** is that some essential media components cannot be cheapened beyond a point – e.g., a growth factor might only function if produced in mammalian cell culture (expensive). Also, any dependency on complex ingredients (like hydrolysates) could introduce batch variability. Mitigation: R&D in synthetic biology is creating **alternatives to costly ingredients** – e.g., engineering yeast to produce growth factors en masse, or finding plant-based substitutes for insulin/albumin. Companies like Multus are key on this front, as are academic innovations (recent Nature Food papers show serum-free formulations with food waste extracts performing well). The UK has strength in bio-manufacturing (from vaccine production etc.) which could pivot to large-scale media ingredient production. But this requires bridging industries (food and pharma regulatory domains merging in novel ways).

"R&D in synthetic biology is creating alternatives to costly ingredients."

8. Risks, Barriers, and Systemic Challenges

- **Product Quality and Complexity**: Another technical barrier is replicating the texture and complexity of conventional meat. It is one thing to grow unstructured cells (for mince), another to create a structured steak with muscle fibres and fat distribution.

  Achieving that marbling and bite of a steak or fibrous texture of chicken breast is extremely challenging Companies like Aleph Farms (cultivated steak) have made progress with scaffold steaks but those are still small (50g prototype) and costly. The **risk** is that cultivated meat can only realistically produce ground meat or processed meat analogues in the foreseeable future, limiting its appeal for certain high-value or culturally important meat formats (e.g., a roast or a whole cut fillet).

  If consumers find the texture inferior or limited to nuggets and burgers, the sector might stall at novelty stage. Mitigation: Tissue engineering advances might gradually allow more complex structures: using 3D printing of cells, or co-culture of muscle and fat cells on advanced scaffolds (e.g. edible collagen scaffolds).

  There's research on electrical or mechanical stimulation of cells to form muscle fibres (like exercise in a bioreactor). UK research hubs (like the Bezos Centre) are exploring how to get whole cuts efficiently. However, an interim strategy is to focus on product types where cultivated meat offers clear quality advantages even unstructured – for instance, cultivated fat for flavour enhancement (Hoxton Farms's approach) or blended products where texture comes from plant proteins and flavour from cultured fat. The UK could carve a niche in hybrid products which deliver 90% of the experience at lower complexity.

- **Bioreactor Infrastructure & Energy**: Building sufficient production capacity is itself a barrier. It is not just a matter of scaling known designs – new factories must be built, which is capital-intensive (e.g. a 121,000 tonne/year facility could cost $1.5–$2 billion by one estimate). Also, these plants will be energy-hungry, to maintain precise conditions and sterilisation. If cultivated meat uses a lot of electricity (for stirring, temperature control, etc.) and that electricity is not green, the climate benefits shrink.

  The **risk** is that scaling up quickly might hit supply chain limits: not enough steel for bioreactors, not enough skilled engineers to build and run facilities, or simply not enough investment (ties into funding barriers). Mitigation: Governments can facilitate by treating cultivated meat plants as strategic infrastructure (like they do for battery factories or semiconductor fabs). They could offer subsidies or streamline planning permissions. Co-locating facilities with renewable energy sources or industrial symbiosis parks (using waste heat etc.) could alleviate energcost and footprint.

  The UK's abundant offshore wind could ideally power these future "biomanufacturing farms" – but only if planning aligns (maybe situating plants near wind farm grid connections). The systemic challenge is ensuring the inputs to cultivation (energy, materials, expertise) are scaled sustainably alongside the process itself.

"The UK's abundant offshore wind could ideally power these future "biomanufacturing farms""

2. Regulatory and Policy Challenges:

- **Regulatory Approval Hurdles**: Every new cultivated meat product must clear rigorous safety assessments. The UK's FSA, like the EU's EFSA, requires detailed data on cell line provenance, absence of contaminants, nutritional profile, etc. This process is time-consuming (estimated ~18-24 months in the UK), and no company has done it in the UK yet. The **risk** is regulatory delays, or overly burdensome requirements could slow market entry to a crawl. If approvals take, say, 3-4 years each, and require expensive studies, many startups might not survive to see their product approved. Additionally, if UK policy diverges from other markets (e.g., requiring different labelling or processes), it complicates scaling for companies wanting to sell internationally. Mitigation: The UK's sandbox approach is an attempt to streamline this. By working closely with companies early (FSA reviewing data as it is generated), they might shorten time to approval by ~6 months (targeting ~2 years instead of 2.5). The FSA also can learn from Singapore/US to avoid reinventing the wheel (regulators have been sharing info internationally to harmonise standards). The risk of regulatory divergence remains though – for example, how to treat genetically modified cell lines. If a company uses a gene-edited cell for efficiency, will UK treat it as GMO (which could complicate approval)? UK's recent Precision Breeding Act allows some gene-edited crops; a similar permissive stance on cell editing could help. The FSA must also manage public perception: being thorough to ensure safety (so as not to lose trust at first incident) but not so ultra-cautious that it effectively shelves the tech.
- **International Regulatory Patchwork**: Different jurisdictions are moving at different speeds. Singapore and a few others are open; the EU might take many years. Italy and some states might ban it outright. This patchwork is a barrier for companies trying to scale globally, because they cannot access all markets at once and cannot leverage one approval everywhere. The risk is companies concentrate production in friendly areas and ignore others, leading to uneven availability and trade tensions (e.g., if one country's farmers feel disadvantaged and lobby for import bans on cultivated meat). For the UK, if the EU remains closed and UK open, could the UK become an exporter to Europe? Possibly, but EU might block imports unless/until EFSA approves (the EU novel food law covers imports similarly). So, the UK could have an approved product that still can only be sold domestically, limiting market size. Mitigation: The UK can work in international forums (Codex Alimentarius, etc.) to establish common safety standards for cell-based foods. If key markets align on essentials, it simplifies things. Also, bilateral agreements could help; perhaps UK-Singapore free trade could include alt-proteins, etc. A unified labelling approach would also be helpful internationally to reduce confusion (e.g., agreeing on terms like "cultivated meat" vs. a proliferation of names). Over time, it is likely more countries will approve as data from early adopters assuage fears, but near term it is patchy.

"The UK can work in international forums to establish common safety standards."

- **Policy Support / Uncertainty**: Apart from product approval, general policy environment is crucial. If governments wholeheartedly support cultivated meat (with R&D funding, consumer education, purchasing for public institutions once available), it helps. If policy is ambivalent or changes with political winds, it creates risk. The UK is currently supportive under an innovation agenda, but that could shift with a different administration or due to lobbying by incumbent agriculture. A policy risk is if, for example, a future government imposes high taxes or strict labelling on cultured meat to placate farming constituencies, or conversely if they remove funding support prematurely, thinking the industry should stand on its own too early. Mitigation: Building a broad coalition of stakeholders (including some farmers) could create a durable political support base for cultivated meat as part of the UK's food strategy. Emphasising constructive interaction (not replacement) with sustainable farming might reduce polarisation. Clear long-term policy signals (like a target or roadmap for alternative protein contribution to UK food) would reduce uncertainty for investors and companies. The UK's National Food Strategy has nudged in this direction, but more concrete commitments may help.

3. Market and Consumer Challenges:

- **Consumer Acceptance & Perception**: Public acceptance is far from guaranteed. Surveys indicate a sizeable portion of consumers are wary or disgusted by the idea of lab-grown meat. Concerns about unnaturalness, safety, and ethics abound. There is also potential for misinformation to spread (e.g., conspiracy-like claims that it's unsafe or "not real food"). If influential voices (celebrity chefs, media, social influencers) take a negative stance, that could seriously impede uptake. Additionally, acceptance might vary: perhaps younger urban consumers embrace it, while older or rural consumers reject it – limiting market size. The **risk** is that even with regulatory approval and supply, demand might be weak due to psychological barriers. In a scenario where cultivated meat cannot shake the "yuck factor," it could remain a novelty that people try once but not regularly purchase, leading to failed commercialisation. Mitigation: Education and outreach are key. As cultivated meat becomes visible through tastings, media coverage of its potential benefits, and endorsements by trusted figures, perceptions can shift. Transparency in production (some startups do video tours of their facilities to demystify it) helps. Also, positioning matters: initial products should shine in quality – e.g., if a cultivated chicken burger tastes amazing and is marketed as a high-tech delicacy with environmental benefits, it might garner curiosity and approval. Over time, normalising language (calling it simply "cultivated meat" and selling it alongside conventional meat, not in a weird separate shelf) can integrate it. The UK government and companies might consider campaigns highlighting that it is real meat, just made differently – drawing analogies to familiar fermentation foods (beer, yogurt) to make it seem less alien. Still, full acceptance might take a generation; interim, targeting receptive segments (millennials, flexitarians) is pragmatic.

- **Price and Economic Viability**: Even if the technology works, if the price is too high, widespread adoption will not occur. Consumers may say in surveys they care about environment, but many still choose foods by price and taste primarily. If cultivated meat cannot reach cost parity or close to it, it will rely on niche affluent consumers or B2B markets (like high-end restaurants). That may not deliver the environmental impact at scale. The **risk** is that costs remain, say, 2-5x higher per kg than conventional meat beyond 2030, making it a luxury product. That would severely limit its ability to displace significant meat production (and correspondingly limit returns for investors). Mitigation: Achieving price reduction is tied to the tech and scale, which we covered. But even if inherently a bit

"Building a broad coalition of stakeholders could create a durable political support base for cultivated meat."

costlier, there might be paths to market via premiumisation. For example, cultivated meat might initially market itself like Wagyu beef or Iberico ham – a superior, ethical product worth paying more for. If framed as a value-added product (no antibiotics, slaughter-free, nutritionally tailored – e.g., healthier fat profile), some consumers will pay a premium. As volumes increase, economies of scale can bring price down. Government incentives could also transiently help, e.g., subsidies for sustainable foods or carbon pricing on high-emission meat. In the UK, if climate policy eventually puts a cost on carbon in agriculture, cultivated meat (with lower emissions) could become economically competitive even if production cost is slightly higher, because conventional meat's price might rise to internalise externalities. That is a big "if" since meat taxes are politically sensitive, but discussions have started in climate circles.

- **Competition with Other Alternatives**: Cultivated meat isn't emerging in a vacuum – it faces competition from plant-based proteins (Beyond, Impossible, etc.), fermentation-derived proteins (Precision fermentation making milk proteins, mycoprotein like Quorn), and improvements in traditional farming (like regenerative agriculture or insect protein as feed reducing livestock impact). If one of these alternatives captures the sustainability-conscious consumer segment more effectively, cultivated meat could struggle to differentiate. For example, if by 2030 plant-based meats taste identical to meat and are cheaper, many might see less need for cultivated. The risk is that cultivated meat arrives "too late" to the alternative protein party or cannot carve a distinct value prop. Mitigation: Cultivated meat's unique selling point is that it is actual animal tissue, so for staunch meat lovers who find plant substitutes lacking, it could be the only convincing alternative. Companies should focus on that authenticity – marketing it to those who would not go plant-based but care about environment or animal welfare. Also, cultivated meat can complement other alternatives: e.g., combine with plant-based to improve them (that constructive collaboration approach means it's not purely head-to-head). The UK's NAPIC is looking at integrated uses of plant and cultivated ingredients, which could yield products superior to either alone. The alternative protein market will be multi-faceted; cultivated meat does not need 50% share to succeed, even 5-10% of global meat market is huge in value. It must ensure it doesn't fall into a tiny <1% niche which is not financially sustainable for industry.

- **Market Structure and Equity**: There is a systemic risk that the benefits of cultivated meat might not be equitably distributed. If the tech is dominated by a few large corporations (say, big meat or big tech companies) controlling IP and production, it could concentrate economic power further, marginalising small producers or developing countries' ability to participate. For instance, could poor countries adopt this, or would they remain reliant on cheap conventional meat (and continue suffering environmental harm)? There is also a risk that early products target only wealthy consumers, doing little for food security where it is needed. Mitigation: Open science initiatives (like open cell lines or public-funded research shared freely) and encouraging a competitive landscape of many players can help avoid monopoly. The UK's stance of license-free tech (Quest's cell lines) and open-access hubs is positive in this regard. Also, as the tech matures, it could be transferred globally – e.g., a modular farm-in-a-box bioreactor that developing countries can use to produce protein without needing vast grazing land. International cooperation (via UN or other agencies) might be needed eventually to ensure global South benefits (the way solar tech eventually got cheap and widespread). While this may be beyond a 10-year horizon, early ethical considerations are good to keep in mind to steer the industry toward inclusive growth and avoid criticism that it is just "food for rich techies."

"As the tech matures, it could be transferred globally."

4. Talent and Knowledge Barriers:

- **Workforce & Skills**: Cultivated meat straddles multiple fields, meaning the workforce needs are specialised. A shortage of skilled tissue engineers, bioprocess engineers, food scientists with fermentation experience, regulatory experts for novel foods, etc., could bottleneck progress. Already, startups globally often compete for a small pool of people with relevant experience. The risk is that lack of talent slows R&D and scale-up or leads to mistakes (like quality control issues) due to inexperienced operators. Mitigation: Education and training programs are ramping up. The UK's new Master's/PhD programs under the Bezos Centre will churn out more experts. Apprenticeships could be developed for biomanufacturing technicians (retraining brewery or pharma techs to work on cultured meat). International hiring is also important – the UK should remain open to global talent (immigration policies for high-skilled workers matter here). Collaboration with allied industries helps too – e.g., hiring from the vaccine manufacturing industry or from plant-based food R&D where some skills overlap. Over a decade, as more universities incorporate cellular agriculture into their curriculum, the talent gap should narrow, but near term it's a constraint that companies often cite as limiting how fast they can go.

- **Public Research and IP Access**: If key breakthroughs are locked behind patents owned by a few companies, which could hinder broader innovation. Conversely, if there's not enough fundamental research (much is happening in startups behind closed doors), basic knowledge might advance slower. A systemic challenge is balancing patent incentives with openness to allow cumulative progress. The UK government investing in open research centres partly addresses this (CARMA, etc., publish a lot). This lowers the risk of a knowledge bottleneck. However, if big corporations start acquiring startups, they may create patent thickets. Mitigation: Ensuring that critical foundational IP (cell lines, certain media formulations) are accessible via licensing on reasonable terms or kept open source can support a healthier ecosystem. The involvement of non-profits like GFI pushing for open databases (they have a cell line repository program) also helps. The UK might consider something like patent pools or consortia where multiple parties share IP to accelerate scale-up (some precedent in other industries).

5. Environmental and Health Unknowns:

- **True Environmental Impact**: It's assumed cultivated meat is greener, but it is not fully proven at industrial scale. If energy is not renewable or if growth media production has hidden emissions, the benefit may be less. A recent study from University of Oxford (2023) even posited that if cultivated meat energy use is high, its CO_2 could accumulate more in atmosphere than methane from cattle (because methane warms strongly but breaks down in ~12 years, whereas CO_2 accumulates) – so climate effect depends on energy source and efficiency. The risk is if analysis in practice shows only marginal GHG benefit or worse, sceptical stakeholders (or the media) could heavily criticise the industry ("cultivated meat not actually eco-friendly!") which would be a PR blow and ethical concern. Mitigation: Continual life-cycle assessment (LCA) is needed, and the industry should be transparent about it. Early adoption should be paired with renewable energy commitments to maximise GHG reduction (even cultivated meat factories could be required or incentivised to use green power). The UK, having a decarbonising grid, gives a better context than say coal-powered regions. Water and land footprints look promising in studies, but monitoring actual resource use as facilities come online will validate that. Ensuring waste from production (spent media, etc.) is handled sustainably (e.g., can any components be recycled or used as inputs for other processes?) is also necessary to keep the environmental promise intact.

"Apprenticeships could be developed for biomanufacturing technicians."

- **Health and Safety**: While expected to be safe (since it's the same cells as in meat but grown sterilely), there could be perceived or real health concerns. For instance, will the nutritional profile be identical (some differences might occur – e.g., maybe slightly different micronutrient levels if not eating varied feed)? If media components or scaffolds are not fully edible, any residue must be checked (the goal is all food-grade, but if any pharmaceutical-grade chemicals were used, those must be eliminated in final product). The **risk** is if any safety scare occurs – e.g., a contamination event, or some unexpected allergic reaction – it could severely set back consumer trust and provoke stricter regulations. Mitigation: Rigorous testing and quality control are paramount. Cultivated meat production actually offers a safety advantage of being in a controlled environment (no E. coli from slaughter, etc.), and no need for antibiotics means less risk of resistant bacteria. Communicating these *health benefits* can counter consumer fears. But companies must not overclaim. Also, labelling should clearly note ingredients – if any novel additives (like scaffold materials) remain in the product, they should be disclosed. Over time, if cultivated meat can be shown to be consistently safer (e.g., no food-borne illnesses, lower saturated fat, etc.), it may become a selling point.

In summary, while the potential of cultivated meat is huge, the road is fraught with challenges that must be proactively managed. The UK, by virtue of foresight and strategic support, can mitigate some of these barriers: leveraging its research power to solve technical issues, crafting smart regulation to enable safe but swift approvals, educating the public, and fostering collaboration rather than conflict between new and old players. The next section on *Signals, Scenarios, and Strategic Outlook* will build on these identified risks and opportunities to outline how the future might unfold under different conditions and what indicators will tell us which path we are on.

> *"Cultivated meat production actually offers a safety advantage of being in a controlled environment with no need for antibiotics."*

9

Signals, Scenarios and Strategic Outlook

Building what matters

9. Signals, Scenarios and Strategic Outlook

Having mapped the drivers, players, and challenges in previous sections, we now turn to the futures perspective: what are the plausible trajectories for cultivated meat over the next decade, and how will we know which future is emerging? In this section, we present a set of **scenarios** for the cultivated meat sector circa 2035, grounded in current evidence but exploring a range of outcomes (from optimistic to conservative). Each scenario integrates the cross-cutting themes of sustainability, economics, technology readiness, consumer attitudes, and policy environment. We also identify **early signals and indicators** to monitor in the coming years that will hint at which scenario is unfolding. The goal is to equip strategic decision-makers – investors, founders, policymakers – with foresight to adjust their strategies in time.

Key Signals to Watch (2025–2030)

Before delving into fully fleshed scenarios, it is worth highlighting some near-to-mid-term signals that will act as harbingers:

- **Regulatory Milestones**: Regulatory approvals (or denials) are top signals. Watch for the **first UK FSA approval** of a cultivated meat product for human consumption – if it occurs by 2025–26 as expected, it will validate the UK as an early adopting market. Similarly, signals like the EU's stance (if EFSA starts evaluating an application, or if Italy's ban proceeds or is struck down) will shape company strategies. A major positive signal would be **China announcing a regulatory pathway** (given its market size; China's 5-year agricultural plan in 2022 explicitly mentioned cultivated proteins as a growth area, so any concrete move by Chinese regulators would be a game-changer).

- **Cost Breakthroughs**: Keep an eye on reported production cost trends from leading firms. If by 2027 multiple companies publicly claim production costs <$10 per pound (and can back it up), that is a strong signal of commercial viability. Conversely, if by 2030 costs are still hovering at ~$50+ per pound in pilot operations, that indicates more time needed. One specific indicator: the **cost of cell culture media per Litre** (already dropped >99% in experiments). If industry sources or GFI report media costs reaching, say, $1/L or less by late 2020s, that is a significant enabling milestone. Another related signal: **bioreactor scale achieved**. Vow's 20,000 L in 2024 is largest so far; if we see announcements of 50,000–100,000 L bioreactors operational by 2030, it signals scale-up challenges are being overcome.

- **Commercial Launches & Sales Figures**: Early market performance will be telling. For example, if GOOD Meat or UPSIDE Foods in the U.S. moves from exclusive restaurant tasting to selling through retail (even in one city) and the product consistently sells out, that signals healthy consumer demand. In the UK, a potential signal in 2025–26: a **high-end restaurant in London puts a cultivated meat dish on the menu full-time** (post-approval) and gets positive reviews or high patron interest. By 2028–2030, track whether cultivated meat products have expanded to mainstream grocery shelves in any country and their price point relative to conventional meat. If by 2030 cultivated meat is available in major UK supermarkets (even in a small section) at, say, no more than double the price of regular meat , that would indicate a strong trajectory toward normalisation.

- **Consumer Sentiment Shifts**: Signals here include survey data and cultural representation. For instance, if Food Standards Agency surveys show willingness to try cultivated meat rising from ~20% to, say, >50% by 2030, that's a huge positive shift. Alternatively, negative signals could be persistent scepticism or a prominent public backlash (e.g., a viral social media movement against "lab meat", or influential food celebrities deriding it). On the cultural front, we might see cultivated meat portrayed positively in media (like a documentary extolling its benefits, or it features on a popular cooking show challenge) – those would be signs of mainstreaming. Another interesting signal: if language and labelling debates resolve – e.g. the UK formally allows it to be called just "cultivated [animal name] meat" and that term enters common usage without much fuss – that suggests acceptance.

- **Industry Investment and Consolidation**: Watch investment flows: after the current dip, does capital return? A signal of high optimism would be a mega-investment (e.g., a $200M+ round or an IPO in late 2020s) or major acquisitions (if, say, Tyson Foods acquires Upside Foods for a hefty sum, indicating a bet that it will scale). On the other side, a negative signal would be multiple startups folding by 2026–27 due to inability to fundraise, implying the timeline was too slow for investors. Also note new entrants: if big food companies start launching their own cultivated R&D divisions (for example, if Unilever or Nestlé start cultivating meat in-house by 2030), that shows they see enough promise to not want to be left behind.

- **Policy Initiatives and Public Funding**: A strong signal in the positive direction is continued or increased government support: e.g., additional UK government funding beyond the initial £75m, such as incentives for building a commercial plant (perhaps similar to how governments incentivise EV battery factories). Internationally, if climate policy frameworks begin to incorporate alternative proteins (for instance, countries including alt-proteins in their official decarbonisation strategies or offering tax breaks for low-carbon foods), that boosts cultivated meat's prospects. Conversely, negative policy signals might be protectionist moves – e.g., more countries proposing outright bans like Italy's draft, or onerous labelling laws that effectively stigmatise the product.

With these signals in mind, we outline **three scenarios** for 2035: **1) Transformation Realised (Optimistic), 2) Dynamic but Limited Growth (Middle Ground),** and **3) Niches and Stagnation (Pessimistic)**. These are not exhaustive, but they capture distinct futures for UK and global cultivated meat.

Scenario 1: Transformation Realised (Optimistic)

In this scenario, cultivated meat over the next decade achieves key technical and economic breakthroughs, leading to broad acceptance and significant market penetration by 2035:

Key Features in 2035 (Optimistic Case):

- **Market Presence**: Cultivated meat constitutes a noticeable share of meat consumption in certain markets. Globally, it might be around **5% of meat supply by volume** (tens of millions of tonnes), and in the UK slightly higher (if proactive) or similar. This implies the sector has grown into a **multi-billion dollar industry (>$20 billion globally)**. Major fast-food chains and retailers offer cultivated meat options side by side with conventional meat. Prices have fallen close to parity for some products – e.g., a cultivated chicken burger at a quick-serve restaurant costs only ~10-20% more than a conventional one.

- **Technology & Cost**: Through continuous innovation, production costs dropped to **around $5–$10 per kg** of meat (near to conventional wholesale meat prices). This was achieved by ultra-efficient 100,000 L bioreactors, fully optimised continuous processes (cells constantly harvested), and cheap media (food-grade components replacing expensive reagents). Many companies use **reusable or recombinant growth factors**, so media cost is negligible. Cell densities of >100 billion cells per Litre are routine, dramatically improving output per run. There is even specialisation: some facilities excel at muscle fibre production, others at fat, and then they combine. The UK's CARMA program yielded open technologies allowing numerous firms to scale up without each solving everything from scratch.

- **Product Range**: A wide array of products is available. Initially ground meats dominated, but by 2035 the industry cracked **structured cuts** – you can buy a cultivated steak that, while still expensive, is a gourmet item. More common are hybrid products; for example, widely consumed are high-quality sausages and meatballs that are ~50% cultivated meat, 50% plant-based (to keep costs down but flavour up). Cultivated seafood (like tuna, salmon) also emerged strongly – being easier in some ways (fish cell culture thrives at lower temperature, etc.). The UK has a niche leadership in, say, cultivated lamb (leveraging its culinary heritage) and exports that to other markets.

- **Consumer Acceptance**: By now, the novelty has worn off and cultivated meat is broadly seen as just another type of meat. Surveys in 2035 show a majority of UK consumers have tried it and many regularly consume it, especially in younger cohorts. It is considered trendy and responsible. There is still a segment who prefer "traditional farm-raised" for various reasons (perceived naturalness), but a similar dynamic exists as with organic vs. conventional foods. Importantly, no major safety issues occurred; in fact, cultivated meat built a reputation for **excellent safety (no recalls for E. coli, etc.)** and slightly healthier profile (some products are designed with less saturated fat). The term "cultivated meat" is mainstream; it even earned an official dictionary definition. Negative monikers ("Frankenmeat") faded as familiarity grew, and the world did not end; much like how early scepticism about things like microwaves or GM insulin subsided when benefits proved out.

- **Sustainability Impact**: Thanks to improvements and renewable energy integration, cultivated meat in this scenario delivered on climate promises. A typical cultivated beef uses ~80% less GHG emissions per kg than 2035 conventional beef (which did get a bit better through methane-reducing feed, but still high). Life-cycle assessments in 2030s show that if powered by renewables, cultivated meat can be nearly carbon-neutral. Many production facilities are run on solar/wind with energy storage, often located in proximity to renewable generation. Land use dropped dramatically – a fact celebrated by conservationists: by 2035, a measurable fraction of farmland in some countries (not the UK yet, but globally) started to be reforested or repurposed as demand for feed crops levelled off. The UK uses cultivated meat as part of meeting its climate targets (food system emissions decreasing instead of increasing). Also, antibiotic use in agriculture is significantly down globally because a chunk of meat is produced without any antibiotics (improving antibiotic resistance outlook). The optimistic scenario sees cultivated meat not as a silver bullet but as a key contributor to a **portfolio of climate solutions** in food, alongside improved plant-based diets and sustainable farming of remaining livestock (which now can be done with more land per animal, reducing intensive practices due to lower volume needs).

- **Industry Structure**: The industry is competitive with dozens of players globally, preventing monopolies. Some did consolidate: a few big meat companies acquired cell-ag startups, but they actually helped scale them up. There are also new giants that grew purely as alt-protein companies. The UK hosts a couple of major production facilities – one in Teesside or Wales repurposing an old industrial site, producing thousands of tons annually and employing hundreds in biomanufacturing roles (these are often cited as green job creators). Developing countries have begun adopting the tech too; maybe Singapore, Israel etc. are exporters by 2035, and larger countries like Brazil or China built domestic cultivated meat factories to reduce import reliance. So, cultivated meat is starting to globalise beyond the initial rich tech-savvy markets.

- **Policy Environment**: Governments strongly support alt-proteins. In the UK scenario, maybe post-2030 the government set procurement goals (like requiring public canteens to source X% alternative proteins, including cultivated). Perhaps there is even a modest carbon tax or stringent emissions rules that conventional meat producers face, further levelling the playing field. Public funding still continues for R&D on improving processes, now more focused on refinements like diversifying species (cultured game meats? etc.) and making production more circular (recycling more inputs). Globally, frameworks exist – e.g., Codex has published guidelines for cell-based foods, harmonising safety standards so a product approved in one major region is easily approved in others. There's relatively free trade in cultivated meat products (some countries even prefer importing cultivated meat to importing grain-fed meat due to land constraints or climate commitments).

Implications in this scenario: It is broadly positive – cultivated meat is on a solid growth trajectory and has begun to deliver environmental benefits. For LPs and investors, those who invested in the 2020s are seeing returns as companies go public or pay dividends, etc. The narrative has shifted from "science experiment" to "growing new economy segment." Some conventional meat producers struggled or adapted (beef demand peaked and declined, hitting cattle farmers unless they shifted to niche premium or moved into cell-ag supply chain). However, workforce transition programs helped – e.g., training farmers to operate bioreactors or shifting them to crop production for media. This scenario would mean the UK is well positioned as a leader (if it fully embraced and got facilities up early). It suggests UK consumers have more choice: for those prioritising ethics or climate,

they can have meat without guilt, which could alter diet trends (maybe per capita meat consumption even rises slightly if guilt is removed and health is managed).

Scenario 2: Dynamic but Limited Growth (Middle Ground)

In this scenario, cultivated meat makes progress but more slowly and remains a small, albeit significant, part of the food system by 2035.

Key Features in 2035 (Middle Ground Case):

- **Market Presence**: Cultivated meat might account for ~0.5% to 1% of global meat supply (a niche, but not trivial). In countries like Singapore or Israel 5-10% of meat consumption, but in most places it is niche. The industry exists and grows, but conventional meat still overwhelmingly dominates. The global market size reaches in the order of $5–10 billion by 2035. In the UK, cultivated meat products are available in some supermarkets and restaurants, but uptake is modest – urban, higher-income, or environmentally conscious consumers form the core market. Price is still a bit premium.

- **Technology & Cost**: Some technical hurdles were solved, but not all. Production cost came down, but not to parity. By 2035 cost of goods is around $20–$30 per kg for common products – cheaper than the $100s of early prototypes, but still ~2-3 times conventional chicken or pork. Companies prioritised the highest value products to sell at those higher prices. Bioreactors scaled to mid-size (10,000 L commonly, maybe a few 20kL like Vow, but not much beyond). Continuous processing works in some lines but yield issues persist in others. Growth media cost dropped a lot (serum eliminated, etc.), but energy and capital depreciation keep costs up. As such, cultivated meat finds a market as a premium, ethical product, but has not undercut traditional meat to ignite a mass transition. Many companies pivoted to hybrid products because pure cultivated was too expensive; e.g. a widely sold item might be a plant-based burger with 10-20% cultivated beef cells for flavour – delivering some of the experience at manageable cost.

- **Product Range & Availability**: Ground and processed forms predominate (nuggets, meatballs, dumplings, blended patties). A few whole cut prototypes exist (e.g., limited edition cultivated steaks served in fancy restaurants at very high price, akin to lab-grown diamond vs natural diamond scenario). Cultivated seafood did somewhat better in niche markets (e.g., cultivated bluefin tuna is a luxury sushi ingredient). Pet food with cultivated meat took a decent slice of the high-end pet food market (because pet owners were willing to splurge for no-slaughter meat for pets). For everyday consumers, cultivated meat is something they might try occasionally, but it is not replacing their weekly grocery purchase of mince or chicken breast – at least not yet in 2035. Instead, it coexists with improved plant-based offerings. Perhaps many processed foods (like certain sausages, ready meals) quietly incorporate a bit of cultivated fat or broth for flavour, but not as a selling point – more as an ingredient.

- **Consumer Acceptance**: Public perception is mixed. By 2035, most people have heard of it; some have tried it. A quarter of the population becomes either regular or occasional consumers. Others remain sceptical or indifferent, especially as price is higher and they might not perceive enough personal benefit. The initial hype has died down, but cultivated meat now has a stable, if small, place in the market similar to, say, organic meat's position in the 1990s – a premium alternative. No major safety scandals occurred (which is good), but also no grand "this will save the world" narrative among average people – it is one of many eco-friendly products.

The term “cultivated meat” is used on packaging with clarifiers (“produced from animal cells, not farmed animals”), which some consumers appreciate, and others find off-putting. Over time, familiarity grows slowly; the generation that grew up with it (Gen Z and younger) are more comfortable and comprise most of the customer base.

- **Sustainability Impact**: Some environmental gains are realised but modest at system level by 2035 because volume is small. For instance, cultivated meat may have prevented some expansion of livestock, shaving a few percentage points off what meat production emissions would have been. But absolute global meat demand still rose due to population and wealth increases, so cultivated meat primarily just supplemented supply. If run on clean energy, its footprint per kg is low, but if production is small relative to the huge conventional sector, global emissions from livestock remain high. There may be a hope that beyond 2035 it could scale more. So, in 2035 climate models show alternative proteins (including plant, insect, and cultivated) start bending the curve of ag emissions slightly downward, but the heavy lifting is still undone. Animal welfare impact is similarly modest – billions of animals are still farmed annually, though perhaps slightly fewer than a worst-case scenario. One notable plus: antibiotic use in livestock might have plateaued or slightly reduced as alternative proteins took over some growth in demand; that is beneficial for antibiotic resistance trends.

- **Industry Structure**: The sector went through consolidation. Many startups from the 2020s either merged or folded by early 2030s when their tech did not scale as fast. A few strong players remain, often those who partnered with big food companies for capital and distribution. For instance, in this scenario, maybe two or three global meat companies (like Tyson, JBS, Cargill) each have a cultivated meat line developed from acquired startups, and they produce at moderate scale. They integrate it as one product segment among many. There is less diversity of players; it is capital intensive, so bigger entities dominated. The UK ended up importing cultivated meat or licensing tech from abroad, since UK startups found it tough to raise the 100s of millions needed to build production plants. The UK does have some specialty producers (Quest and others still exist providing cell lines, media, etc., which is an export business for UK), but the mass production might happen where energy is cheapest, or policy is friendliest. For example, the Middle East (with cheap solar) or US (with huge investment capacity) might host big facilities, and UK just buys from them unless it heavily invested otherwise.

- **Sustainability Impact**: The government supportive tone remained but with limited intervention. By 2030, seeing the industry not exploding as fast, governments stepped up a bit with incentives to keep it going (like renewed R&D funding in advanced biomanufacturing). Or they might focus efforts on other climate solutions if they perceive cultivated meat ROI as slow. But at least regulations are in place: UK, EU, etc. have approval processes that companies know how to navigate, albeit still lengthy. No additional burdensome laws came (e.g., labelling rules settled on neutral terms). There might even be some government purchasing: e.g., maybe the military or space agencies used cultivated meat for specialised needs (it’s been discussed for astronauts or remote deployments), which provided some steady demand and public validation.

Implications in this scenario: Cultivated meat is viable but not revolutionary by 2035. Founders who promised to transform the meat industry had to temper expectations. It found a foothold, as part of a broader alt-protein strategy. Investors see some returns but more modest (break-even or moderate profits for those who stayed for long haul, while many initial investors lost out in the shakeout). From a climate perspective, it is a start but not the end – further policy measures might be considered to curtail conventional meat emissions (like promoting feed additives for cattle to cut methane, or stronger deforestation curbs) since cultivated meat did not displace enough yet.

However, the foundation is laid for continued growth. Perhaps by 2035 in this scenario, a new wave of tech improvements (like AI-optimised cell lines, or cheaper bioreactor materials) is coming, suggesting cultivated meat could still expand more in the 2040s. It's a marathon, not a sprint. For those in it, the aim is to **keep costs trending down and acceptance trending up** steadily. The UK in this scenario might re-evaluate how to boost the sector – forging partnerships or creating a dedicated alt-protein innovation cluster to try to accelerate moving from niche to mainstream beyond 2035.

Scenario 3: Niches and Stagnation (Pessimistic)

In this scenario, many of the challenges prove too difficult or take much longer to solve, and cultivated meat remains a scientific curiosity or ultra-niche product by 2035, with the grand vision unfulfilled in the period.

Key Features in 2035 (Pessimistic Case):

- **Market Presence**: Cultivated meat's global market share is negligible, **<0.1% of meat supply**. It is not commercially present in most countries. Only Singapore and a couple of places have any products regularly available, and those are small-scale and expensive. Many people in 2035 still have not encountered cultivated meat in daily life. The whole sector might be valued at only ~$1 billion or less worldwide by 2035, stalling out after initial hype.

- **Technology & Cost**: Key breakthroughs did not materialise by 2035. Scaling issues remained intractable. Bioreactors beyond a few thousand Litres experienced problems (contamination, cell yields crashing, etc.), so companies could not scale economically. As a result, cost of production stayed extremely high – still **>$50–$100 per kg** in pilot runs. Only generous venture subsidies or rich investor funding allowed any production at all, often selling at a loss for PR rather than profit. Growth factors, while cheaper than in 2020, still add considerable cost because some could not be replaced effectively. Also, some technical disappointments: e.g., some companies found their initial cell lines could not adapt to large-scale conditions and had to start over. This scenario could see companies pivoting away (using their tech for more lucrative cell therapy or lab reagent markets instead) or closing.

- **Product Availability**: Very few products hit the market. Only one or two novelty items: e.g., Eat Just's cultivated chicken remained in a couple of Singapore restaurants as a novelty dish for wealthy eco-tourists. Pet food treats like Meatly's might be among the only real-world products sold (since pet owners are a small enough market that tiny production suffices). But even that might be limited if

production costs did not drop – one can only charge so much for a dog treat. No retail presence to speak of, beyond one or two trial runs that did not expand. By 2035 the concept is still in R&D/pilot phase broadly. It is reminiscent of how something like fusion power has had working prototypes for decades but never fully commercialised – similarly, cultivated meat might be "always 5-10 years away" in this scenario.

- **Consumer Perception**: The broader public may have tuned out or become cynical. Early excitement turned to disillusionment as years passed with no affordable product. People might remember the $300k burger news and joke that "lab meat was a fad that didn't pan out." If any products did reach some consumers, they were extremely expensive (like $100 nuggets) and thus mostly just a tech curiosity consumed by a handful of tech enthusiasts or served in one Michelin-star restaurant for the spectacle. Consumer trust could also have been hurt if any poor-quality or weird tasting versions got out – for example, maybe a company rushed a product that had off-flavours or textural issues, and it got panned in reviews, cementing the notion that "it doesn't taste good" in the public mind (even if that was just one instance).

- **Sustainability Impact**: Essentially none. Conventional meat production continued to rise through the 2020s and 30s as population and demand increased, offset partly by uptake of plant-based proteins (which did better than cultivated). Livestock emissions kept growing until strong climate policies specifically targeted them (through other means like improved practices or a shift to plant diets). Cultivated meat's theoretical benefits remained largely on paper. If anything, some retrospective analysis in the 2030s might say, "We spent so much R&D on cultivated meat for little return, perhaps we should've focused differently." It could become a case study in tech optimism failing if not careful. However, some positive byproducts might have emerged: e.g., in trying to reduce media cost, researchers discovered cheaper cell culture techniques that help medicine or other fields.

- **Industry and Investment**: Most dedicated startups either folded or pivoted. By 2035, a lot of initial players are gone. A few might survive as IP holding companies or doing low-volume specialty stuff (like supplying cell lines or media to academia or pharma, not for food). Large food corporations put their initiatives on hold after not seeing results, or never fully engaged seeing costs. A trickle of public funding may still support academia exploring it, but private capital moved on. The field lives on quietly in research labs or a couple of government projects (e.g., NASA or militaries might still invest for unique use-cases like long-term space or submarine missions, where cost is no issue, but self-sufficiency is vital).

- **Policy Environment**: With no tangible industry, regulators might not even finalise frameworks – e.g., the EU might still have no approvals because few bothered applying, or they outright banned it due to pressure from traditional sectors with no strong counter-lobby. The UK's sandbox might quietly close if no companies come forth with viable dossiers. Focus shifts to supporting other alt-proteins which showed more promise. Possibly, cultivated meat might even face extra political resistance if it was framed as a waste of taxpayer money or an approach that detracts from promoting more immediate solutions like shifting diets to plant-based or improving conventional farming. In worst case, some high-profile negative narrative (like a politician calling it "Frankenfood" and rallying sentiment against it) could mean even if tech improves later, public policy might be biased against it due to early disappointments.

Implications in this scenario: This is obviously a setback for those who championed cultivated meat. It doesn't necessarily mean the concept is dead forever – technology could take longer and see a resurgence later (like AI winters and summers historically). But it means in the 10-year horizon, it was not a solution at scale. For climate goals, it puts more pressure on alternatives: heavier promotion of plant-based diets, possibly more radical measures like taxes on meat or rapid advancements in feed and breeding to cut livestock emissions. For investors in this scenario, most lost their money; only those who pivoted their tech to something else salvaged value. For policymakers, it is a lesson in cautious optimism – ensure diversified strategies to decarbonise food, not rely on one silver bullet. And for farmers, business-as-usual, even a relief for many who feared displacement – although they still face climate pressure from other angles.

One hope in such a scenario might be that knowledge gained (in cell biology, bioreactors, etc.) could yet yield breakthroughs beyond 2035 that finally propel the field, but that is speculative. Within our horizon, this scenario is one where cultivated meat fails to get off the ground commercially in any meaningful way.

These scenarios illustrate a spectrum. The reality may not exactly match one but somewhere between the middle and optimistic if supportive actions are taken – or between middle and pessimistic if obstacles prove very tough. They are meant to guide strategic planning:

- In the **optimistic scenario**, cultivated meat contributes materially to sustainable food, and those involved should scale up rapidly and seize market share, with policymakers integrating it into climate strategies and phasing out worst practices in livestock.

- In the **middle scenario**, cultivated meat is part of the solution set but requires further innovation and policy push (like internalising environmental costs of conventional meat) to expand beyond niche.

- In the **pessimistic scenario**, it's back to the drawing board for cell-ag; resources would shift more to other solutions (like precision fermentation for meat analogues, or deeper demand-side dietary changes, or regeneratively farmed meat as a compromise).

Indicators Table: To summarise, here is a simple table aligning some quantifiable indicators with scenarios:

Indicator (2030–2035)	Scenario 1: Transformation	Scenario 2: Limited Growth	Scenario 3: Stagnation
Cultivated meat cost (wholesale $/kg)	~$5–10	~$20–30	>$50–100
Global market share by volume	~5% (multi-region adoption)	~0.5–1% (niche in some regions)	~0.1% or less (novelty only)
Consumer willingness (UK willing to try/eat)	>60% (broad acceptance)	~30–40% (slowly growing)	<20% (persistent scepticism)
# Countries with approvals & products	20+ countries	5–10 countries	<5 (only early adopters or none expanded)
Largest bioreactor size in operation	≥100,000 L	10,000–20,000 L	1,000–5,000 L (pilot scale only)
Active cultivated meat firms (global)	dozens (incl. big players)	<10 significant ones	0–3 (very few, mostly R&D)
Price vs. conventional (retail)	~1–1.5× at premium	~3–5× (remains premium)	n/a (not in retail, except experimental)
UK production capacity & facilities	UK has ≥1 industrial facility	UK has pilot/demo plants only	No dedicated UK facility (lab only)
Alt protein share of UK diet (all types)	~20% (with cultivated contributing)	10% (mostly plant-based, little cultivated)	8% (almost all plant-based; cultivated negligible)

(The above numbers are illustrative, based on narrative; actual outcomes could vary.)

9. Signals, Scenarios and Strategic Outlook

Strategic Outlook: As of 2025, we see signposts that could lead toward any of these scenarios. The present trajectory suggests a middle path: significant innovation but also recognition that timelines may be longer for scale. For the UK specifically, decisions made in the next 2-3 years (on funding scale-up, on regulatory agility, on fostering public-private collaboration) will heavily influence whether the UK trends more toward scenario 1 (leading and benefiting), scenario 2 (following and using others' tech in niche ways), or scenario 3 (letting the opportunity slip).

Thus, the strategic outlook for stakeholders:

- **Investors**: Prepare for multiple outcomes – have milestone-based financing that can ramp up investment in scenario 1 or cut losses early if scenario 3 signals appear (e.g., if cost curves not improving by late 2020s). Engage in sector consortia to share risk (e.g., funds pooling to build one demonstration plant rather than each company struggling alone).

- **Founders/Companies**: Focus on de-risking core cost drivers and have pivot options. Collaborate rather than overpromise – for instance, share enabling tech pre-competitively (like standard cell lines) to ensure the whole field moves ahead, since a failure of the field would sink all players (scenario 3).

- **Policymakers**: Use adaptive regulation – if scenario 1 signals show (fast progress), be ready to integrate alt-protein goals into climate policy strongly, update dietary guidelines, etc. If scenario 3 signals show (stalling), consider whether to increase research funding or shift focus to other methods to achieve food sustainability. Keep international cooperation to avoid regulatory fragmentation that could hinder scenario 1 or 2.

- **Incumbent Meat Industry**: In scenario 1, those who engaged early will be ahead (e.g., producing cultivated products themselves); in scenario 3, it is status quo but they would still face climate pressure eventually. The outlook advice for them is to do low-regret moves: invest modestly in cultivated R&D (like JBS, Tyson did) so that if scenario 1 unfolds they are not left out but not bank everything on it. Monitor tech signals to scale investment accordingly.

In conclusion, while uncertainty remains, the coming 5 years will be decisive in revealing the cultivated meat trajectory. By tracking the signals outlined – cost breakthroughs, regulatory wins, consumer uptake in initial markets – we will know by 2030 if cultivated meat is on the road to transforming food or if it will need a longer gestation (or pivot into other adjacent successes). The strategic decisions made by UK investors, innovators, and policymakers now can shape which of these futures materialises, and how well the UK is positioned in each case.

"The coming 5 years will be decisive in revealing the cultivated meat trajectory."

10

Implications for LPs, Founders and Policymakers

The foresight analysis above yields several clear implications for key stakeholder groups. To conclude, we distil **tiered recommendations** – targeted guidance for Limited Partners (LPs) and investors, startup founders, and policymakers – to navigate the next decade in the cultivated meat sector. These recommendations are structured to be actionable and prioritised, helping each group mitigate risks and capitalise on opportunities, whether the sector accelerates or faces headwinds.

For Limited Partners and Investors (Venture and Institutional):

1. **Adopt a Long-Term, Portfolio Approach**: Cultivated meat is not a quick win, so LPs should back funds (or direct investments) with patient capital and a 10+ year horizon. Accept that revenue ramp may lag other sectors. Mitigate risk by treating alternative proteins as a portfolio – include plant-based, fermentation, and enabling tech plays alongside pure cultivated meat bets. This ensures that even if pure cultivated adoption is slower, adjacent successes (e.g., in foodtech ingredients) can provide returns.

2. **Phase Investments via Milestones**: Structure financing in tranches tied to key technical milestones – e.g., achieving certain cost per kg or bioreactor scale. This protects against over-capitalising ventures that cannot overcome fundamental barriers and encourages startups to focus on critical path innovations. For example, an investor syndicate might commit $X million now and reserve 2–3x $X for follow-ons if cell density and cost targets are met in pilot runs. This milestone funding strategy will help channel money to the approaches that genuinely de-risk production.

3. **Support Collaborations and Shared Infrastructure**: Investors (especially consortia of LPs or government co-investors) should encourage portfolio companies to share knowledge and even facilities. Consider funding shared pilot plants or centres of excellence – e.g., a large-scale bioprocess facility in the UK accessible to multiple startups (similar to the pharma sector's contract manufacturing orgs). This reduces duplicative capital expenditure and accelerates learning by doing. As LPs, be willing to fund industry-wide initiatives (via GFI or trade bodies) that develop open-source cell lines or media formulations, since these can lift the whole sector (and improve the odds of your investments succeeding).

4. **Evaluate Strategic Partnerships Early**: Look for co-investment or exit opportunities with strategic players (large food corporations, specialty ingredient firms). Given that scaling to market requires distribution and manufacturing muscle, bringing in strategics can validate technology and provide follow-on capital. LPs should facilitate introductions and deals where a big food company might take a minority stake or form a JV with a promising cultivated meat startup – providing not just money but regulatory expertise and route-to-market. This strategy also creates optionality for trade sale exits if IPO windows are far off.

5. **Monitor Key Indicators & Stay Agile**: Use the signals discussed (cost per kg trends, regulatory approvals, consumer polls) as KPIs in your investment thesis. For instance, by 2027, if no product has achieved <$20/kg or if regulatory progress stalls, reassess and pivot focus to other alt proteins or enabling tech. Conversely, if by 2025 a UK or EU regulatory approval happens and pilot products get good reception, that's a green light to double-down. Build flexibility into mandates to seize emerging sub-sectors – e.g., if cultured fat for hybrid products shows traction, allocate funds there even if whole-cut meat lags.

10

bappla
Building what matters

"Bringing in strategics can validate technology and provide follow-on capital."

For Startup Founders and Operators:

1. **Focus on Cost Reduction & Tech Feasibility as Priority #1**: However compelling the vision, no cultivated meat startup will survive without credible progress on unit economics. Founders must concentrate R&D on removing expensive inputs (eliminate FBS and costly growth factors), improving cell growth rates, and increasing bioreactor yields. Glamorous marketing or extravagant product demos should take a backseat to engineering breakthroughs Set concrete internal benchmarks (e.g. achieve >X cells/mL density, media <$Y per Litre by a certain date) and track them rigorously. Transparently communicate these metrics to investors to build confidence that you are tackling the hard problems head-on.

2. **Pursue B2B and Hybrid Models for Early Revenue**: Given the challenges of scaling whole meat products, consider near-term revenue via enabling products or hybrid applications. For example, supply cultivated fat or flavour components to plant-based food companies (a market demand exists for better flavour binding). Or target pet food or supplements (less stringent regulation, as Meatly did for dog treats). These can provide cash flow, real-market feedback, and iterative improvement while you develop full products. Founders of "full stack" meat companies should weigh partnerships where your cells could integrate into an established brand's product (e.g., a plant-based brand using your cultivated beef flavour in a burger). These de-risk commercialisation and builds your credibility.

3. **Collaborate, Do not Reinvent the Wheel**: Embrace a pre-competitive collaboration mindset with peers. Share non-differentiating tech (like basic cell line traits, general scaffold materials) so everyone can advance faster. Join and actively participate in consortia (UK's Cellular Agriculture UK, international alliances, GFI working groups) to both contribute and glean knowledge. Leverage open research from CARMA, NAPIC etc. – for instance, if an academic group publishes a cheaper media recipe, adopt it rather than each startup clinging to proprietary (but unproven) formulas. Collaboration can also extend to physical resources: co-rent bioprocess space or collectively hire expensive expertise (like regulatory consultants) to share costs. Remember, the competition is not other startups – it is the conventional meat value chain, and consumer scepticism; a rising tide will lift all boats at this stage.

4. **Design for Regulation and Safety from Day 1**: Proactively integrate regulatory compliance, food safety, and quality control into your development process. Engage with the UK FSA's sandbox or novel foods team early – present your approach, ask what data they will expect, and build those studies into your plan (toxicity assays, allergenicity, etc.). Document everything (cell line history, media ingredients traceability) meticulously; this will save time in approval and inspire confidence (regulators and consumers). Also, design your process with **scalability and GMP standards in mind** – for instance, if you plan to use a scaffold or enzyme, ensure it's food-grade and scalable in supply. Founders who treat regulators as partners rather than obstacles will be first to market. Additionally, prioritise consumer safety unequivocally – one lapse could set the field back significantly. Build redundancy and monitoring in your production, even at pilot scale, to prove that cultivation in bioreactors can be even safer than farm/hygiene conditions.

"Design your process with scalability and GMP standards in mind"

5. **Narrative and Transparency – Build Public Trust**: As you solve technical issues, do not neglect the **story and engagement**. Founders should lead in demystifying cultivated meat – open your lab doors virtually (share videos of your process, highlight the science). Engage with food influencers, chefs, and media in honest dialogue about what cultivated meat is and is not. Avoid hype that sets unrealistic expectations (like claiming near-term price parity if it's far off). Instead, emphasise the concrete benefits you are working toward: e.g., "Our process uses 80% less land and we've cut medium cost by 90% so far, and with further R&D we aim to approach price parity for certain products by 20XX." Humanise the technology – show that it is a natural cellular process, just done in clean stainless-steel tanks rather than in an animal. By building trust gradually through **transparency and educational marketing**, you will prepare the market and mitigate backlash when products launch. Additionally, engage with farmers and workers who might be impacted – e.g., consider pilot partnerships where a farmer becomes a cultivation plant operator, to show inclusion. A well-crafted narrative can turn potential opponents into allies (for example, framing cultivated meat as complementary – freeing farmers to focus on higher-welfare, regenerative practices for the conventional meat that remains).

For Policymakers and Government (UK and similar contexts):

1. **Create an Enabling Regulatory Framework with Agility**: Policymakers should ensure **clear, science-driven, and efficient regulation** for cultivated products. The UK's early moves – funding FSA's sandbox and engineering biology vision – are commendable. Build on this by publishing **transparent guidelines** for novel food dossiers specific to cultured cells (e.g., what molecular data or toxicology tests are expected). Set service standards for approval timelines (aim for that 18-24 month goal and strive to shorten without compromising rigor). Consider implementing a "provisional approval" mechanism for limited market tests once core safety is shown, to gather real-world data (similar to Singapore's approach). Also, coordinate with international regulators (US FDA/USDA, EFSA, SFA Singapore) on **harmonising safety standards** – this will encourage companies to invest in the UK knowing they can potentially export or expand easily. Use the sandbox results (two products by 2025–26) as templates to refine processes. Policymakers must walk a line: uphold food safety (no shortcuts that would risk an incident) but eliminate unnecessary red tape. Make the UK the place where cultivated meat companies want to base their R&D and pilots because they know the regulatory path is navigable and science-based.

2. **Deploy Targeted Funding and Incentives for Scale-Up**: Government support should not stop at basic R&D. The critical gap now is translating lab success to factory. Consider **co-investing in a national pilot production facility or a "Cellular Agriculture Accelerator"** – akin to how governments have innovation hubs for semiconductors or vaccines. For instance, an InnovateUK or UKRI program could fund cost-sharing grants for the first demonstration plants (10,000+ L scale), on condition that data is shared and multiple companies can utilise the facility (this reduces duplication and spreads benefit). Explore **tax incentives** for alt-protein manufacturing – e.g., capital allowances or tax credits for building bioreactors, similar to incentives for green energy. Another idea: incorporate cultivated meat into **public procurement once approved** (serve it occasionally in government canteens, military rations, hospital menus). This provides initial demand and public visibility. Also, continue upstream funding in open research for bottlenecks (like funding university projects on serum-free media, novel scaffolds, cell line optimisation – these directly feed industry needs). Such targeted support can accelerate the timeline to cost reduction and ensure the UK captures the economic benefits (jobs in biomanufacturing, intellectual property, etc.) of this emerging sector.

10

bappla
Building what matters

"Engage with food influencers, chefs, and media in honest dialogue about what cultivated meat is."

3. **Integrate Cultivated Meat into Climate and Agricultural Policy**: Recognise cultivated meat as a strategic tool to meet climate, environment, and food security goals. In upcoming policy documents (like carbon budgets, Nationally Determined Contributions under Paris Agreement, agricultural transition plans), explicitly reference sustainable proteins including cultivated meat. For example, update the UK's carbon accounting to include potential emissions savings from alternative proteins, and build scenarios where cultivated meat supplies X% of protein by 2035 to hit climate targets. This signalling will justify supportive measures and funding. On agricultural policy: engage farming communities in planning – fund **transition programs** (retraining or new business models) for livestock farmers who might one day be affected. For instance, pilot schemes where a farmer cooperative partners with a cell-ag startup (farmers could supply renewable energy or feedstock inputs like grain for media). Ensure cultivated meat is not seen as adversarial to rural interests; instead, emphasise it can improve resilience (e.g., mitigating zoonotic disease risk, providing new tech jobs in rural bioprocessing facilities). By embedding cultivated meat into high-level policy frameworks (like the UK's food strategy or net-zero strategy), policymakers give it legitimacy and align stakeholders on a common direction.

4. **Public Education and Transparency Initiatives**: Government agencies (FSA, Defra, Public Health bodies) should take an active role in **educating the public** about cultivated meat – its safety, how it is made, its benefits and limitations. Consider public information campaigns or including it in school curricula under food science, to normalise the concept for the next generation. Support independent research on nutritional and health aspects (to answer questions like: is cultivated meat healthier, the same, or different nutritionally?). Publicly share findings – for instance, if studies show no antibiotics and lower contamination, amplify that message. At the same time, be transparent about what is unknown or under study so as not to overhype. An informed public discourse, led by trusted neutral entities, can prevent polarisation and build consumer readiness. Government could also facilitate **stakeholder dialogues** – bring together consumer groups, animal welfare NGOs, farmer unions, and scientists to discuss concerns and expectations around cultivated meat, potentially finding common ground (for example, animal welfare groups might become champions if assured of safety and benefits, farmers might soften opposition if they see inclusion and economic opportunity). The government acting as convener and honest broker will lend credibility to the cultivated meat narrative.

5. **Monitor Progress and Be Ready to Adjust Strategies**: Policymakers should keep a pulse on the industry's progress via the **signals and milestones**. If by late 2020s it's clear cultivated meat is hitting targets (scenario 1 track), then plan for more aggressive integration: e.g., examining how regulatory frameworks (like labelling laws, tax regimes) might evolve when these products become common. Possibly prepare to update meat definitions in regulations, or to negotiate trade rules including cultivated meat. Conversely, if progress is slow or scenario 3 looms, allocate resources accordingly – focusing more on other alt-proteins or demand-side measures, but still supporting the underlying science in case breakthroughs eventually occur. Essentially, maintain a flexible policy stance that can scale support up or down based on empirical progress. This could involve periodic formal reviews (e.g., a 2027 government review of alternative protein tech status, with stakeholder input, to course-correct policies). Being neither prematurely all-in nor disengaged, but dynamically responsive, will ensure government interventions are efficient and goal-aligned.

10

bappla
Building what matters

"Government agencies should take an active role in educating the public about cultivated meat."

In conclusion, the next decade for cultivated meat will be pivotal. The UK and similar jurisdictions have a chance to lead and shape how this technology unfolds. By implementing the above recommendations, **investors can wisely allocate capital, founders can navigate from lab to market, and policymakers can foster a fertile ecosystem**. The rewards of success – a more sustainable food supply, new industries and jobs, reduced climate and ethical burdens – are enormous. The risks of failure, while real, can be mitigated with collaborative effort and prudent strategy. All stakeholders should act with both **ambition and realism**: push the boundaries of innovation and scale yet remain grounded in scientific reality and transparent engagement. By doing so, the UK can help ensure that if and when cultivated meat arrives on our plates en masse, it does so safely, affordably, and in a way that benefits society broadly – from investors and entrepreneurs to farmers, consumers, animals, and the planet.

10

bappla
Building what matters

“The next decade for cultivated meat will be pivotal.”

11

Acknowledgements

Building what matters

11. Acknowledgements

First and foremost, we are grateful to **Pera Internationa**l for sponsoring the research.

Special thanks to **Mark McGraw** and **Pete Riley (Spooky Nook Creative Limited)** for their support in editing and stylising the report and helping with publication.

The Kappika Futures Reports are produced using a **“best of both”** policy that reflects our commitment to combining the strengths of human insight and artificial intelligence. These reports are co-created by experienced analysts and researchers working alongside advanced AI tools, ensuring a process that is both rigorous and efficient.

AI contributes by accelerating data processing, surfacing patterns, and expanding the scope of analysis—while human judgment ensures contextual interpretation, strategic relevance, and editorial integrity. Together, this hybrid approach enables us to deliver timely, thoughtful, and commercially valuable foresight to founders, investors, and stakeholders across the UK innovation landscape.

12

Appendices

Building what matters

12. Appendices

Glossary

- **Cultivated Meat (Cell-Cultured Meat)**: Animal meat produced by cultivating animal cells directly in a controlled environment (bioreactors), instead of raising and slaughtering animals. Also known as cultured meat, lab-grown meat, cell-based meat.
- **FBS (Foetal Bovine Serum)**: A nutrient-rich fluid derived from calf foetuses, historically used as a growth supplement for cell culture. Its removal/replacement is crucial for ethical and cost reasons in cultivated meat production.
- **Bioreactor**: A vessel or tank in which cells are grown under controlled conditions (temperature, pH, nutrients). In cultivated meat, bioreactors (also called cultivators) can range from small laboratory scale to potentially 10,000+ Litre industrial tanks.
- **Scaffold**: A structural support (often edible or biodegradable material) on which cells attach and grow, used to create 3D tissue structure in cultivated meat (especially for thicker or whole-cut products).
- **Cell Line**: A population of cells derived from an initial primary source that can proliferate over time. In cultivated meat, stable cell lines from livestock species (cow, pig, chicken, etc.) are used as the starting point for cultivation.
- **Hybrid Product**: A food product combining cultivated meat components with plant-based ingredients. Often pursued to enhance flavour/texture while keeping costs lower than 100% cultivated content (e.g., a plant-based burger with cultivated fat).
- **Novel Food Regulation**: Food safety regulations (especially in UK/EU) for approving foods that do not have a significant history of consumption. Cultivated meat falls under this and must be assessed for safety before sale.
- **CARMA / NAPIC**: UK research initiatives – Cellular Agriculture Manufacturing Hub (CARMA) and National Alternative Protein Innovation Centre (NAPIC) – funded to advance alt-protein science and engineering.
- **Good Food Institute (GFI)**: A non-profit think tank promoting alternative proteins; provides research, data, and policy advocacy in cultivated meat and plant-based sectors. Often cited for industry stats and analyses.

12. Appendices

References

1. Quest & Multus partnership announcement – describing UK efforts to cut cultivated meat costs through new media and scaffolds.

2. Good Food Institute – State of the Industry reports, providing data on number of companies, investment totals, and progress in 2024.

3. UK Parliamentary POSTnote on Cultivated Meat (2025) – outlines UK context, including first pet food approval and cost estimates ($16 to $400k/kg).

4. Food Processing Magazine – news on UK's first cultivated meat approval (pet food, 2024) and global context of regulatory firsts (Singapore, US, Israel).

5. GFI Europe – overview of UK alternative protein research centres (CARMA, NAPIC, etc.) demonstrating strong public research support in UK.

6. Adopter Tech Statistics (2025) – compiles industry statistics like McKinsey's 0.5% by 2030 prediction and Allied's market size estimates to gauge scenario benchmarks.

7. Reuters – report on JBS's cultivated beef plant (world's largest planned, 1000+ tons/year by 2024) showing incumbents' significant investments.

8. FSA/FSS Consumer Research (2024) – indicates only 16-41% of UK consumers willing to try cultivated meat now, but 59% see benefits, 85% have concerns, underlining importance of public education.

9. AgFunderNews (Elaine Watson, 2025) – "No silver bullets to fill funding gaps" highlights steep decline in funding ($1.3B in 2021 to $139M in 2024) and need for government & alt financing.

10. Ivy Farm case (AgFunder, 2022) – UK pilot plant example and Oxford Economics projection of $15B global, $1.7B UK market by 2030, plus 92% emission reduction stat from CE Delft, reinforcing optimistic scenario potential.

kappika

Building what matters

A UK venture capital firm backing early-stage deep tech.
Building what matters with clarity, conviction, and capital.

www.kappika.com